



(86) Date de dépôt PCT/PCT Filing Date: 2011/07/28
(87) Date publication PCT/PCT Publication Date: 2012/02/02
(85) Entrée phase nationale/National Entry: 2013/01/18
(86) N° demande PCT/PCT Application No.: US 2011/045693
(87) N° publication PCT/PCT Publication No.: 2012/016021
(30) Priorité/Priority: 2010/07/28 (US61/368,453)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2006.01),
A61K 31/7048 (2006.01), *A61K 31/4709* (2006.01)

(71) Demandeur/Applicant:
VERIDEX, LLC, US

(72) Inventeurs/Inventors:
VENER, TATIANA I., US;
DERECHO, CARLO C., US;
PALMA, JOHN F., US;
RAPONI, MICAL, US

(74) Agent: NORTON ROSE CANADA
S.E.N.C.R.L./S.R.L./LLP

(54) Titre : PROCEDES DE DETERMINATION DE REPONSE DE LA LEUCEMIE MYELOIDE AIGUE A TRAITEMENT
PAR INHIBITEURS DE LA FARNESYLTRANSFERASE
(54) Title: METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH
FARNESYLTRANSFERASE INHIBITORS




FIG. 8

(57) **Abrégé/Abstract:**

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib,

(57) **Abrégé(suite)/Abstract(continued):**

paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1 : APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (RI 15777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 February 2012 (02.02.2012)(10) International Publication Number
WO 2012/016021 A3(51) International Patent Classification:
G01N 33/48 (2006.01)(21) International Application Number:
PCT/US2011/045693(22) International Filing Date:
28 July 2011 (28.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/368,453 28 July 2010 (28.07.2010) US(71) Applicant (for all designated States except US):
VERIDEX, LLC [US/US]; 1001 Us Highway Route 202,
North Raritan, NJ 08869 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VENER, Tatiana, I.** [US/US]; 285 Mercer Street, Stirling, NJ 07980 (US). **DERECHO, Carlo, C.** [US/US]; 311 Pine Street, Lakehurst, NJ 08733 (US). **PALMA, John, F.** [US/US]; 7393 Sitio Lima, Carlsbad, 92009 (US). **RAPONI, Mitch** [NZ/US]; 2417 Woolsey Street, Berkeley, CA 94705 (US).(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i))

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS




FIG. 8

(57) Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatin. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1 : APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R1 15777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipifarnib and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

WO 2012/016021 A3



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- (88) Date of publication of the international search report:**
3 May 2012

METHOD OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS

Background

5 Acute Mylogenous Leukemia (“AML”) has a low prevalence in the US at about
50,000 patients, which is believed to be well below the 200,000 patients required for
being labeled as an orphan disease. The prevalence of AML is greater in older patients,
in whom the disease also tends to be far more difficult to treat. Elderly patients, typically
defined as being at least 60 years old (although some classifications require patients to be
10 above at least 65 or even 70 years old), succumb to the disease at a far higher rate.
Response (to treatment) rates and survival in elderly AML patients average 30% to 50%
for a complete recovery with a median relapse-free survival (RFS) of only about 9 to 12
months. Very few elderly patients survive beyond 2 years.

 Managing the treatment of elderly AML patients presents many challenges.
15 Although about seventy percent (70%) of patients achieve remission of AML with
conventional induction therapy, because of the toxic effects of the therapy and extremely
poor outcome in elderly patients, conventional induction therapy is often not offered to
the elderly. The treatment options for elderly patients, then, are often little more than
investigational treatments or palliative care. Nevertheless, it is possible to identify sub-
20 groups of elderly patients that are likely to respond to conventional induction therapy.
For instance, elderly patients with favorable cytogenetics and without elevated multiple
drug resistance protein (MDR1) expression respond well to induction therapy. However,
delay in identifying such patients resulting in a delay in the initiation of induction
therapy, for instance, while waiting for results of the cytogenetic evaluation—which may
25 take a week or so to be completed—has a markedly deleterious effect on the prognosis.
Other markers of poor response include the presence of the FLT3/ITD mutation, or the
expression of the CD34 antigen. Thus, effective management of elderly AML patients’
treatment requires quick decisions, which, in turn, requires rapid assays to select the
appropriate treatment. Some patients respond well to treatment while others decline and
30 suffer from the side-effects.

 AML patients may also be divided into those having relapsed/refractory disease
and those with newly diagnosed disease. A relapsed or refractory disease state patient

has either become non-responsive to treatment or the disease has returned. Either relapsed or refractory state is associated with poor prognosis.

Unfortunately the initial success of many AML treatments is often followed by relapses. Further, most treatments are not known to be effective in all patients and partial
5 remission is largely ineffective in prolonging survival.

Farnesyl transferase inhibitors (FTIs) offer an alternative treatment even in elderly patients. Farnesyl transferase inhibitors (FTIs) inhibit the covalent attachment of the carbon farnesyl moieties to the C-terminal CAAX motif of various proteins. FTIs, significantly, appear to be better tolerated by elderly patients than conventional induction
10 therapy. But, only about 15% to 25% of the patients respond to treatment with a farnesyl transferase inhibitor. Farnesyltransferase inhibitors, such as Tipifarnib, function by competitively inhibiting the addition of a farnesyl moiety to signaling molecules such as RAS that are implicated in cancers. Such inhibition is expected to hamper their function. Many FTIs of interest for this disclosure are described in US Patent Publication
15 20030050323.

Tipifarnib, also referred to as R115777 or its trade name ZARNESTRATM, the first farnesyltransferase inhibitor (FTI) to be tested in the clinic, has shown promise for treating many diseases. It has demonstrated significant activity in hematological disorders including AML, multiple myeloma (MM), Myelodysplastic Syndrome (MDS),
20 juvenile myelomonocytic leukemia (JMML), myelofibrosis with myeloid metaplasia (MMM) and chronic myelogenous leukemia (CML), with complete response rates in AML and MDS of up to approximately 15%. Moreover, Tipifarnib often acts synergistically with other treatments. This synergy often provides an elderly patient with few other options, the ability to undergo treatment with a farnesyl inhibitor in
25 combination with another agent while having tolerable side-effects and superior outcomes than with treatment just one agent in isolation. Notably, prior clinical trials of tipifarnib by itself did not lead to noticeable increase in survival, and some combinations with other agents, such as Cytarabine ('ara-C') may even have increased mortality. The combination of tipifarnib with etoposide appears to overcome such drawbacks.

30 The preferred FTI, tipifarnib, inhibits the growth of many tumors/cell lines. In particular, cell lines expressing N-ras or H-ras mutations exhibit significant inhibition of

cell proliferation. However, only about half of cell lines with K-ras mutations, when tested, were inhibited by FTI R115777 and then too at much higher doses. FTI R115777 also exhibited synergy with many agents in inhibiting the growth of tumors/cell lines. Notably, some cancers and other proliferative disorders are characterized by mutations in
5 or sensitivity to different types of ras mutations. Accordingly, FTIs, including R115777, are not expected to be equally efficacious in treating all types of cancers and proliferative disorders. Indeed, where K-ras plays an important role, FTIs are unlikely to be as effective as when only N-ras or H-ras have an important role.

Another set of alternative treatments to conventional induction therapy are based
10 on Podophyllotoxin and are described in US Patent Publication US20030050323. Podophyllotoxin is extracted from the mandrake plant. It is the parent compound from which two glycosides have been developed which compounds show significant therapeutic activity in several human neoplasms, including pediatric leukemia, small cell carcinomas of the lung, testicular tumors, Hodgkin's disease, and large cell lymphomas.
15 These derivatives are etoposide (VP-16) which has the chemical name 41-demethylepipodophyllotoxin-9-[4,6-0-(R)-ethylidene-beta-D-glucopyranoside] and teniposide (VM-26) which has the chemical name 41-dem ethylepipodophyllotoxin-9-[4,6-0-(R)-thenylidene-beta-Dglycopyranoside]. These compounds' mechanisms of action involves the induction of DNA strand breaks by an interaction with DNA
20 topoisomerase II or the formation of free radicals. Both etoposide and teniposide, however, cause toxic side-effects especially myelosuppression.

To increase the inhibitory efficacy of anti-tumor podophyllotoxin derivatives against tumor growth and also to provide a means for the use of lower dosages of anti-tumor podophyllotoxin derivatives, synergistic combinations with other treatments have
25 been explored. FTIs, and in particular, tipifarnib, exhibit synergies with etoposide, which allows less toxic effective doses—a significant consideration in elderly AML patients.

The side-effects from a combination of tipifarnib and a derivative of Podophyllotoxin, such as an etoposide, are more tolerable. However, unlike the seventy percent (70%) response rate in younger AML patients, the response rate to a combination
30 of etoposide and tipifarnib typically ranges from about 15% to 25%. Since not all AML

patients respond to treatment with FTIs, it is not desirable to treat a patient with FTI if the patient is unlikely to respond, which presents a challenge prior to administering the FTI.

Although the preferred FTI, R115777, has been effective in combination therapy, it has not been possible to reliably predict such synergy between R115777 and other
5 agents in a particular patient, in part because the extent of inhibition of farnesyl transferase activity does not correlate well with clinical changes. For instance, the mutation status of the *RAS* gene was considered to be a candidate biomarker for patient response to FTIs. This rationale was based on pre-clinical evidence that specific point mutations within the *RAS* genes cause constitutive activation of the RAS Pathway in
10 many cancers. It is generally accepted that with tumors heavily reliant on the activation of one or two pathways, patients with such tumors should respond to drugs that inhibit those pathways. However, sometimes many pathways can be activated by multiple events and it has been found that RAS can be up-regulated in the absence of activating *RAS* mutations. Furthermore, no correlation between *RAS* mutations and response to
15 FTIs has been demonstrated in clinical studies as has been pointed out in US Patent Publication 20070048782, which is incorporated by reference herein in its entirety. Indeed, while several early clinical studies of FTIs focused on cancers that exhibited high frequencies of *RAS* mutations, the response rate was disappointingly low in those trials. Thus, the problem of predicting the response of a particular patient to farnesyl transferase
20 inhibitors in combination with other treatments awaits a suitable diagnostic assay that is rapid, accurate and affordable to make the prediction ability clinically useful.

Summary

This disclosure identifies markers that predict response to treatment with a combination of a farnesyl transferase inhibitor and an etoposide. These markers enable identification of an oncology therapy with a low response profile that is not withheld
5 from potential responders while avoiding subjecting likely non-responders to undesirable side-effects.

The preferred embodiments allow reliably and rapidly predicting if a particular patient is likely to respond to an FTI combination treatment, which treatment includes an FTI with one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel,
10 temozolomide, topotecan, trastuzumab and cisplatinum. A preferred FTI combination treatment comprises tipifarnib with etoposide. Further, this disclosure meets the need to select the most effective treatment among many possible treatments, and to switch to a more effective treatment. One of the goals of treating AML, with its multiple causes, complications and treatments, is to timely and accurately predict the effectiveness of a
15 particular treatment in a patient, especially if the patient is elderly. The disclosed personalized predictions of likely response to FTI combination treatments should allow the potentially non-responsive patients to be offered alternative treatments while treating likely responders with FTI combination treatments.

Preferred treatments include, tipifarnib, which is an orally available,
20 nonpeptidomimetic farnesyltransferase inhibitor with demonstrated complete recovery rates in AML and MDS of up to 15% in myeloid malignancies including in elderly adults with AML who are not candidates for traditional cytotoxic therapy. Tipifarnib is also effective in high-risk myelodysplasia, and myeloproliferative disorders including agnogenic myeloid metaplasia and imatinib resistant chronic myelogenous leukemia.
25 Significant improvements in this response rate are desirable to avoid dosing patients with tipifarnib who are highly likely to be non-responsive to it.

The method, for identifying whether a subject diagnosed with a myeloid disorder is a candidate for FTI combination treatment, comprises administering a first assay having a first outcome. If this outcome, or the reciprocal of this outcome, is less than a
30 predetermined threshold, then the subject is flagged as unlikely to be aided by a first group of treatments, each of which requires administration of a farnesyl transferase

inhibitor in combination with an agent selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. If the subject is not flagged, then a treatment from the group of treatments is selected for administration to the subject.

5 The choice of the predetermined threshold is preferably such that the subject is flagged if there is a high negative predictive value for benefit from a treatment selected from the group of treatments to avoid denying effective treatment to as large a group as may be reasonable. Thus, effectively the high negative predictive value requires flagging subjects least likely to be aided by treatment with the farnesyl transferase inhibitor in
10 combination with another agent. It should be noted that flagging a subject may be either a positive act—determining that the subject will likely benefit from a treatment—or a negative act—determining that the subject will not benefit from a treatment. Thus, flagging should also be understood as identifying a group or even defining a group.

 Alternatively, the choice of the predetermined threshold can be such that the
15 subject is flagged if there is a high positive predictive value for benefit from a treatment selected from the group of treatments to improve the likelihood of benefit from the treatment. This typically will be favored if there are many competing treatments available that can be distinguished from each other.

 Further, even for subjects identified as likely to benefit from a treatment selected
20 from the group of treatments, the treatment is selected based on a relative positive predictive value of the treatment—preferably relative to other treatments in the group. In a preferred embodiment, the myeloid disorder is acute myeloid leukemia.

 In another aspect, the disclosed method may also be used to identify whether, in response to detecting a reduction in a subject's response to a past treatment, the subject
25 should be switched over to a different future treatment. The different treatments may include a palliative treatment. Alternatively, the different treatment may comprise a different combination of an FTI with a medication like etoposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatinum.

 A positive predictive value of a treatment with a Farnesyl transferase inhibitor in
30 combination with another agent is determined based on a fraction of subjects expected to exhibit a positive response to the treatment, wherein the positive response comprises

complete remission, wherein, further, complete remission is defined by the presence of less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/ μ L and a platelet count of at least 100,000/ μ L, absence of blasts in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-
 5 associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease.

In addition, in a preferred embodiment, the positive response further includes partial remission, wherein partial remission is defined by presence of trilineage hematopoiesis in the bone marrow with recovery of ANC and platelets to the above stated
 10 levels, but with 5 to 25% bone marrow blasts, and at least 50% decrease in bone marrow blast percentage from baseline. Further, in another preferred embodiment, the positive response further includes hematologic improvement. Hematologic improvement is defined by at least a 50% decrease in marrow blasts or decrease in any measurable extramedullary disease, recovery of ANC to 500 to 1000/ μ L, platelet count to 20,000 to
 15 100,000/ μ L, or improvement in transfusion requirements.

In a preferred embodiment of the disclosed method a level of expression of genes *RASGRP1* and *APTX* is estimated using a polymerase chain reaction (PCR). The PCR reactions may be performed in a single tube together with a reference PCR reaction. The sample for such amplification may be one or more of (i) a bone marrow sample; and/or
 20 (ii) a blood sample. The ratio of the expression levels of two markers, *RASGRP1* and *APTX*, may be estimated using an external normalization control. In a preferred embodiment, amplification of amplicons comprising
 CTGGACGATCTCATTGACAGCTGCATTCAATCTTTTGATGCAGATGGAAACCT
 GTGTCGAAGTAACCAACTGTTGCAAG SEQ No. 1 for *RASGRP1* and
 25 CGCTTCCGATTGGGCTACCACGCCATTCCGAGTATGAGCCATGTACATCTTCA
 TGTGATCAGCCAGGATTTTGATTCT SEQ No. 2 for *APTX* is undertaken using the primer pairs selected from the group consisting of

- (i) 5'-CGCTTCCGATTGGGCTAC-3' SEQ No. 3 *APTX* upper primer
- (ii) 5'- AGAATCAAAATCCTGGCTGATC-3' SEQ No. 4 *APTX* lower primer,
- 30 (iii) 5'- CTGGACGATCTCATTGACAGC-3' SEQ No. 5 *RASGRP1*, upper primer, and

(iv) 5'- CTTGCAACAGTTGGTTACTTCG -3' SEQ No. 6 *RASGRP1*, lower primer.

The performance and utility of two-gene expression ratio (*RASGRP1:APTX*) in predicting a clinically meaningful response to FTIs like R115777, *RASGRP1* and *APTX* was identified by studying bone marrow from older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for *N-RAS* mutations using global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (*RASGRP1:APTX*) as providing the greatest accuracy for predicting response to tipifarnib. This classifier predicted response to tipifarnib in patients with relapsed or refractory AML, with a negative predictive value and positive predictive value of 92% and 28% respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier may be implemented with the aid of qPCR, using which in a study a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50% respectively (odds ratio of 4.3) were observed. Such data indicate that a simple two-gene expression assay can be used to identify AML patients who are likely to respond to tipifarnib (R115777). Further, the two-gene assay may be used not only in newly diagnosed patients, but also in those exhibiting refractory or relapsed AML, for instance following induction therapy, and for providing maintenance therapy.

In an exemplary embodiment, a rapid two-gene ratio *RASGRP1:APTX* is determined by the steps of collecting a peripheral whole blood sample, isolating the RNA from the sample, amplifying the amplicons described above using the primers described above, amplifying in the same set of reactions the amplicons described above in Universal RNA or another external control—a reference that includes *RASGRP1* and *APTX* RNA species, measuring the C_t values for each reaction, rejecting samples or reactions in which the C_t is above 40 cycles, more preferably rejecting samples or reactions in which the C_t is above 37 cycles, even more preferably rejecting samples or reactions in which the C_t is above 35 cycles and most preferably rejecting samples or

reactions in which the Ct is above 30 cycles. Then, the *RASGRP1:APTX* ratio is calculated as described next.

$$RASGRP1:APTX \text{ ratio} = 2^{-(A-B)-(C-D)}$$

Where A: Sample RasGRP1 Ct value

5 B: JY (or Universal) RNA (+) RasGRP1 Ct value

C: Sample APTX Ct Value

D: JY (or Universal) RNA (+) APTX Ct Value

Outcome rendered by the assay is compared against the response. To estimate assay performance, Area under the Curve (AUC) value is preferably calculated based on
10 Receiver Operator Characteristic (ROC) curve analysis, for instance, using a MedCalc software package.

In the preferred method, if the ratio exceeds a predetermined threshold, then the patient is classified as being a likely responder. Else, the patient is a non-responder. The predetermined threshold is defined by, preferably, the AUC corresponding to the desired
15 assay performance or another performance criterion such as sensitivity or specificity or a maximized sum of sensitivity and specificity. Thus, the particular threshold value may differ, for instance, due to the reference RNA (Y or Universal or another RNA set) used, but the specification desired performance of the threshold in stratifying patients allows use of different reference RNA and other experimental conditions in an RTPCR assay
20 while generating comparable patient stratification.

This disclosure allows selection of a threshold, wherein the ratio of expression levels *RASGRP1* and *APTX* is compared to the threshold, for identifying a responder to a treatment with a combination of a farnesyl inhibitor and another agent, which is selected from or is a derivative of a member selected from the group consisting of etoposide,
25 teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatin. The selection of the threshold, in a preferred exemplary embodiment, comprises processing a blood sample to generate a ratio of expression levels *RASGRP1* and *APTX*. The threshold is selected to increase one or more of a measure from the set consisting of a positive predictive value of the treatment, a negative predictive value of
30 identifying a responder, an AUC in a ROC analysis, a sensitivity and a specificity. In a preferred embodiment, the expression levels of *RASGRP1* or *APTX* are measured using

RT-PCR although other methods of measuring expression of a gene of interest may be substituted.

It should be noted that instead of Universal RNA (from STRATAGENETM another external control RNA may be used with no loss of generality. However, the predetermined threshold for the *RASGRP1:APTX* ratio may need to be adjusted. The predetermined threshold may be evaluated using a ROC analysis so as to keep the AUC constant. For instance, using JY RNA (obtained from the JY cell line) as a reference a threshold of 5.2 was determined. Switching to the more widely available standardized Universal RNA resulted in an adjustment of the threshold to 7.3 to ensure that AUC was consistent. The difference in the threshold reflects the different relative presence of *RASGRP1* and *APTX* in the reference RNA. Other reagents may further make a difference in the threshold calculation.

In addition, the threshold may also be adjusted based on the sensitivity or specificity requirements—if any. Thus, when putative non-responders are candidates for an alternative therapy then it is advisable to select a threshold to maximize the number of patients eligible for either therapy to improve the overall likelihood of combating AML in the most patients. In this regard, in view of the ability of younger patients to undergo induction therapy with relatively high remission rates, a different threshold may be used when evaluating such younger patients for treatment with a FTI, alone or in combination with another agent, than the threshold used to evaluate elderly patients who are not offered the induction therapy. Such a threshold may be chosen to reflect a high specificity to identify patients highly likely to respond to treatment with an FTI like tipifarnib. Alternatively, induction therapy in combination with an FTI, even though not known to be synergistic, will provide the patients with timely effective treatment—timeliness being a critical factor in combating AML. This ensures that patients are not denied possible therapy.

Optionally, in an exemplary embodiment, RNA from HMBS is also amplified and detected to check on sample integrity so that an abnormally low value of HMBS RNA flags the sample as being questionable. For HMBS RNA a preferred amplicon is

CCTGCCCACTGTGCTTCCTCCTGGCTTCACCATCGGAGCCATCTGCAAGCGGG
AAAACCCTCATGAT Seq. No. 7, which is amplified using the primers

CCTGCCCCACTGTGCTTCCT SEQ No.8 HMBS upper primer, and
ATCATGAGGGTTTTCCCGCT, SEQ No. 9 HMBS, lower primer.

The detection of the amplicons is preferably made using the following probes:
FAM-CATTCAATCTTTTGATGCAGATGGAAACCTG-BHQ1, RASGPR1, Taqman
5 probe, SEQ No. 10;
Gold 540-CACGCCATTCCGAGTATGAGCCATGTAC-BHQ2, APTX, TaqMan probe,
SEQ No. 11; and
Cy5-GCTTCACCATCGGAGCCATCTGCA-BHQ1, HMBS, TaqMan probe, SEQ No.
12. As will be readily noted, the probes can be varied not only in the choice of the
10 sequences but also as to the specific tags used on them with little loss of generality.

This disclosure also demonstrates that the two-gene ratio *RASGRP1:APTX* can be
rapidly assayed by qPCR performed in a single tube using standardized reagents. This
assay has predictive utility in identifying likely responders among newly diagnosed AML
as well as relapsed or refractory AML patients—including elderly patients. Further the
15 assay can use a peripheral blood sample instead of the customary bone marrow sample,
obtaining which requires a far more invasive a procedure than that required to obtain the
peripheral blood sample.

The two-gene ratio is useful in a method for prescribing tipinifarb to a subject
diagnosed with a myeloid disorder. In one such method evaluation of the expression of
20 *RASGRP1* and *APTX* is made in a sample, such as bone marrow or blood, by
amplification of signals from ribonucleic acid targets using at least one primer from the
group consisting of

- (i) 5'-CGCTTCCGATTGGGCTAC-3'
- (ii) 5'- AGAATCAAAATCCTGGCTGATC-3'
- 25 (iii) 5'- CTGGACGATCTCATTGACAGC-3' and
- (iv) 5'- CTTGCAACAGTTGGTTACTTCG -3'.

Next, the level of expression of genes *RASGPR1* is estimated relative to one or
more of the group consisting of expression levels of *APTX*, beta-actin and *HMBS*,
preferably in a single tube in a multiplex format. The ratio of expression levels of
30 *RASGRP1* relative to *APTX* is determined. If the ratio in a subject is greater than a
threshold, which preferably is about 5.1 or about 5.2, the subject is prescribed tipifarnib.

In a preferred embodiment, tipifarnib is prescribed with another agent synergistic with tipifarnib. Such an agent may be one of or a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatinum. The most preferred
5 administration is of tipifarnib and etoposide.

The invention also facilitates a method for administering tipinifarb and etoposide to a patient diagnosed with a myeloid disorder. As before, it is first determined if the ratio of RASGRP1 and APTX expression exceeds a threshold of about 5.1 or about 5.2. And, if the ratio exceeds this threshold, tipifarnib is administered. These and other details are
10 described next with the aid of the following figures, many of which together with parts of the specification are based on, and shared with, the US Patent No. 7,932,036, which is hereby incorporated by reference.

Brief Description of the Drawings

Figure 1 depicts the performance of the RASGRP1 gene as a predictor of response to tipifarnib in AML. The accuracy rates (A) and Kaplan-Meier survival curves (B) using the RASGRP1 gene classifier in newly diagnosed AML.

5 Figure 2 depicts the performance of the RASGRP1:APTX gene pair as a predictor of response to tipifarnib in AML. The overall survival of newly diagnosed AML patients (A) and relapsed/refractory AML patients (C) stratified with the 2-gene classifier are plotted using Kaplan-Meier analysis. The accuracy rates of the two-gene classifier in newly diagnosed AML (B) and relapsed/refractory AML (D) are shown.

10 Figure 3 depicts the performance of RASGRP1:APTX gene classifier using qPCR. (A) The normalized RASGRP1:APTX Ct values for 20 responders and 10 patients with progressive disease. The 20 independent samples and 10 training samples that were run on microarray are shown separately. Horizontal bars indicate group means. (B) The accuracy rates of the RASGRP1 gene classifier in newly diagnosed AML for all 30
15 patients are shown using a cutoff of 0 was used to stratify patients. (C) The associated overall survival of the stratified patients are plotted using Kaplan-Meier analysis.

Figure 4 depicts the performance of the RASGRP1 gene as a predictor of response to tipifarnib in relapsed and refractory AML. The accuracy rates (A) and Kaplan Meier survival curves (B) using the RASGRP1 gene classifier in
20 relapsed/refractory AML.

Figure 5 depicts the overall survival of non-FIT treated AML patients stratified with the RASGRP1:APTX gene expression ratio. Three cDNA probes for both RASGRP1 and APTX were present in the available data set. We first calculated the mean value for each gene and then calculated the RASGRP1:APTX ratio of these values.
25 Patients whose ratio was above 1 were classified as progressors and those with a ratio below 1 were classified as responders. Kaplan-Meier analysis was then performed.

Figure 6 depicts the correlation of Affymetrix and qPCR data. Nine RNA samples that were analyzed on both the Affymetrix GeneChip and by qPCR were compared by linear regression analysis. The Y-axis is used to plot the qPCR values in the
30 form of a normalized Δ Ct corresponding to a ratio of *RASGRP1:APTX*. It should be noted that this value, strictly speaking, is not a ratio but a normalized Δ -Ct corresponding to the

ratio even though the terms are used interchangeably. As a result, as the level of *RASGRP1* increases, its corresponding Ct value decreases and all else being the same, the Δ Ct value decreases. The X-axis represents the corresponding *RASGRP1:APTX* ratio values generated from the array data for the same samples, which values increase as the ratio increases. As a result the slope of the line showing the correlation between the normalized Δ -Ct and the array generated *RASGRP1:APTX* ratios is negative.

Figure 7 depicts the amplification of RasGRP1, APTX and HMBS RNA in a triplex format in a single tube showing the required close correspondence, low variability and high reproducibility.

Figures 8 and 13 depict accuracy of the improved qPCR assay in a Phase 2 study of tipifarnib + etoposide study in elderly AML using Kaplan Meier analysis of patients stratified using an optimal ratio cutoff 5.2..

Figures 9 and 14 depict the ROC analysis indicating a discriminative value of the 2-gene ratio as 80% (AUC= 0.80) for predicting overall response with a complete remission (CR) patient group used as the response criteria.

Figures 10 and 15 show there is no association between the 2-gene ratio and clinical response or overall survival in patients not treated with an FTI. Overall survival of 41 AML patients treated with intensive induction chemotherapy with ara-C, anthracycline, and a third agent (flavopiridol or etoposide): stratification by high vs. low 2-gene ratio.

Figure 11 depicts the work flow for comparing and determining the preferred sample collection problem.

Figures 12A and 12B show the effect of the sample collection protocols on the result of the two-gene assay. Figure 12B in particular shows the scatter for each patient illustrating the effect of the sample collection protocol. The Y-axis shows the ratio of *RASGRP1:APTX* in the sample to the *RASGRP1:APTX* in a calibration/reference RNA, which in this case is JY RNA. Thus, the value on the Y-axis is a ratio of ratios arrived at by the $\Delta\Delta$ Ct method. The threshold used in the preferred assay is a threshold based on a desirable stratification of patients using the $\Delta\Delta$ Ct method for quantitating the levels of *RASGRP1* and *APTX*.

Detailed Description

The therapeutic agents referred to in this specification include FTIs. They take on a multitude of forms but share the essential inhibitory function of interfering with or lessening the farnesylation of proteins implicated in cancer and proliferative diseases.

5 Preferably, the FTIs are those indicated for the treatment of leukemias such as AML.

Numerous FTIs are within the scope of the disclosure and include those described in US Patents 5,976,851; 5,972,984; 5,972,966; 5,968,965; 5,968,952; 6,187,786; 6,169,096; 6,037,350; 6,177,432; 5,965,578; 5,965,539; 5,958,939; 5,939,557; 5,936,097; 5,891,889; 5,889,053; 5,880,140; 5,872,135; 5,869,682; 5,861,529; 5,859,015; 5,856,439; 10 5,856,326; 5,852,010; 5,843,941; 5,807,852; 5,780,492; 5,773,455; 5,767,274; 5,756,528; 5,750,567; 5,721,236; 5,700,806; 5,661,161; 5,602,098; 5,585,359; 5,578,629; 5,534,537; 5,532,359; 5,523,430; 5,504,212; 5,491,164; 5,420,245; 5,238,922 and US Publication 20030050323. Non-peptidal, so-called "small molecule" therapeutics are preferred.

More preferred FTIs are quinolines or quinoline derivatives such as:

15 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-2,3-dihydro-1H,5H-benzo[*ij*]quinolizin-5-one,

7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1,2-dihydro-4H-pyrrolo[3,2,*i*]-quinoline-4-one,

8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4H-pyrrolo[3,2,*i*]quinolin-4-one, and

20 8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-2,3-dihydro-1H,5H-benzo[*ij*]quinolizin-5-one. The most preferred FTI is (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone).

25 It is desirable to classify response to treatment to facilitate both understanding of the effect of the treatment and to compare different treatments. There are many criteria for evaluating treatments. For instance, a count of a thousand neutrophils may suffice to identify a response in some embodiments, while other embodiments may require 1,400 or 1,500 neutrophils. Similarly, the platelet count may vary anywhere from 30 100,000 to 140,000. And, improvement in one cell line of a certain percentage may be required or in other evaluations improvement in two or even improvement in all three cell

lines. The time duration over which such changes are determined may range from one month or two months or even more. In a preferred embodiment, a patient who responds to an FTI is one in whom at least a reduction of more than 50% of blast cells is seen in bone marrow following treatment with the FTI. Typically, the degree of improvement
5 required for partial response tends to be variable, and improvement represented by hematologic improvement is extremely variable between evaluations by different investigators and/or physicians. Alternative similar standards to evaluate a response to the administration of an FTI are intended to be within scope of claims directed to predicting response to treatment—unless a contrary intent is expressly indicated.

10 In a preferred embodiment, positive responses to treatment comprise rates for Complete Remission (CR), Partial Remission (PR), and Hematologic Improvement (HI). The remaining disease descriptors are Progressive disease (PD) with the remainder of the non-responders adjudged to be exhibiting Stable disease (SD). Each of the positive responder classifications are described next.

15 Complete remission (CR) may be marked by bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/ μ L and a platelet count of 100,000 μ L, absence of blasts in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary
20 disease. A CR must be confirmed 4 to 6 weeks after the initial documentation. If possible, at least one bone marrow biopsy should be performed to confirm the CR. With CR it is expected bone marrow will appear to be normal with fewer than five percent blasts, normal maturation, and no dysplasia. In the peripheral blood, a haemoglobin of greater than 11 grams, neutrophils of over 1,500 per millimeter squared and platelets over
25 100,000, no blasts, and no dysplasia will be encountered. Further, to consider AML cured, ideally the risk of relapse in a patient with CR must be the same as the risk of AML in the general population.

Partial remission (PR) is preferably identified by the presence of trilineage hematopoiesis in the bone marrow with recovery of ANC and platelets to the above stated
30 levels, but with 5 to 25% bone marrow blasts, and at least 50% decrease in bone marrow

blast percentage from baseline. A PR must be confirmed 4 to 6 weeks after the initial documentation.

Hematologic Improvement (HI) is preferably marked by at least 50% decrease in marrow blasts or decrease in any measurable extramedullary disease, recovery of ANC to
5 500 to 1000 μ L, platelet count to 20,000 to 100,000 μ L, or improvement in transfusion requirements.

Stable disease (SD) is identified by any response to treatment not meeting CR, PR, HI, or PD criteria.

Progressive disease (PD) is marked by any one of the following:

- 10 • >50% increase in bone marrow blast percentage from best assessment
- >50% increase in circulating blasts
- New appearance of circulating blasts (on at least 2 consecutive occasions)
- Development of extramedullary disease
- In patients who present with an initial marrow blast percentage sufficiently high
15 to preclude the ability to base disease progression on a >50% increase in marrow blast percentage, disease progression should be based upon peripheral blood criteria, new appearance of circulating blasts (on at least 2 consecutive occasions), and/or development of extramedullary disease.

The duration of response is preferably measured from the time measurement
20 criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. The duration of CR is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented.

The duration of stable disease is measured in patients with stable disease from the
25 start of the treatment until the criteria for progression are met.

Progression-Free Survival ("PFS") represents the time between study entry and the first date of objective documentation of recurrent or progressive disease, or the occurrence of death from any cause. Overall Survival is measured from time of enrollment onto this study to time of death.

30 The mere presence of nucleic acid sequences having the potential to express proteins or peptides ("genes") within the genome is not determinative of whether a

protein or peptide is expressed in a given cell. Whether or not a given gene capable of expressing proteins or peptides does so and to what extent such expression occurs, if at all, is determined by a variety of complex factors. Irrespective of difficulties in understanding and assessing these factors, assaying gene expression can provide useful information about the cellular response to a given stimulus such as the introduction of a drug or other therapeutic agent. Relative indications of the degree to which genes are active or inactive can be found in gene expression profiles. The gene expression profiles are used to identify and treat patients who will likely benefit from a given therapy or exclude patients from a given therapy where the patient likely would experience little or no beneficial response to the drug or therapy.

Preferred methods for establishing gene expression profiles (including those used to arrive at the relevant biological pathways) include determining the amount of RNA that is produced that can code for a protein or peptide. This is accomplished by reverse transcription PCR (RT-PCR), competitive RT-PCR, real time RT-PCR, differential display RT-PCR, Northern Blot analysis and other related tests. While it is possible to conduct these techniques using individual PCR reactions, it is best to amplify copy DNA (cDNA) or copy RNA (cRNA) produced from mRNA. Some methods for determining gene expression can be found in US Patents 6,271,002; 6,218,122; 6,218,114; and 6,004,755.

One preferred method involves computing the two-gene ratio *RASGRP1:APTX* to determine whether a person is likely to respond to the use of an FTI therapeutic agent. The term 'ratio' or the 'two-gene ratio *RASGRP1:APTX*' as applied to gene expression values has a range of technical interpretations in this disclosure that are readily discerned from the context. At a basic level the meaning is the same although the form may differ. For instance, when using qPCR techniques, a ΔC_t value corresponding to a ratio of two genes of interest is readily generated, as is well known to one having ordinary skill in the art. This value may be generated by using normalized C_t values for the expression levels of each of the genes by for instance, subtracting the mean C_t value for that gene and dividing by the standard deviation in the C_t values for that gene. The difference between such normalized C_t values for the two genes, the ΔC_t value, corresponds to the ratio of expression of the genes in that as the ratio increases, the ΔC_t value decreases and vice-

versa. Examples of such normalized ΔC_t values are seen on the Y-axis of Figure 6 for *RASGRP1* and *APTX*. Such ΔC_t values, or even normalized ΔC_t values may be referred to as the two-gene ratio *RASGRP1:APTX* in this disclosure. An example is in Figure 3A which shows a threshold of 0 in terms of ΔC_t value on the Y-axis such that responders are below the threshold. This threshold of 0 corresponds to a threshold of 1 when two-gene ratio *RASGRP1:APTX* is expressed in terms of array data, such as those plotted along the X-axis of Figure 6. Figure 6 merely illustrates that it is readily possible to go from one way of determining the *RASGRP1:APTX* ratio to another. Alternatively, the ratio may be expressed as a positive number based on the $\Delta\Delta C_t$ value, which compares various samples to a standard calibrator/reference RNA. Use of such a common calibrator makes an assay more portable and reliable since the threshold can and does change based on the experimental conditions since the threshold is primarily defined by its performance in stratifying patients in a test environment. In a preferred embodiment using RTPCR, the two-gene ratio *RASGRP1:APTX*, expressed as a positive number based on the $\Delta\Delta C_t$ value as described elsewhere in this disclosure, leads to a value of 5.2 for stratifying responders to tipifarnib from non-responders to tipifarnib. Example two-gene ratio values of *RASGRP1:APTX*, expressed as a positive number based on the $\Delta\Delta C_t$ values, are plotted on the Y-axis of Figure 12B and are also referred to as two-gene ratio *RASGRP1:APTX* with the context making clear which interpretation should be used. Strictly speaking, a person having ordinary skill in the art will realize that a threshold or two-gene ratio *RASGRP1:APTX*, expressed as a value based on one or more of the $\Delta\Delta C_t$ value, in terms of array data, as a ΔC_t value and just the $\Delta\Delta C_t$ value while comparable may not lend themselves to ready interconvertability in the absence of additional information to aid in such a mapping. The claims and description herein should be read in light of this consideration. The two-gene ratio *RASGRP1:APTX* is indicated, for clarity, as the two-gene $\Delta\Delta C_t$ ratio *RASGRP1:APTX* or the two-gene ΔC_t ratio *RASGRP1:APTX* or the $\Delta\Delta C_t$ threshold or the ΔC_t threshold, but when such clarification is not provided the context readily provides the correct interpretation.

Having established a threshold to distinguish a responder from a non-responder, the two-gene ratio is fixed in a medium such as a computer readable medium as described below. A patient sample is obtained that contains diseased cells (such as hematopoietic

blast cells in the case of AML). In a preferred embodiment, sample RNA is then obtained and amplified from the diseased patient cell and amplified using PCR and the two-gene ratio calculated with the aid of an external normalization control. Then, in a preferred embodiment, if the two-gene ratio is greater than a predetermined threshold, the patient is identified as a likely responder, else as a non-responder.

In similar fashion, the two-gene ratio can be used to monitor response to a treatment comprising an FTI at various periods throughout the course of treatment. If the two-gene ratio is consistent with a responder then the patient's therapy is continued. If it is not, then the patient's therapy is altered. Such analysis permits intervention and therapy adjustment prior to detectable clinical indicia or in the face of otherwise ambiguous clinical indicia.

Preferred embodiments may cover representations of the gene expression profiles useful for treating, diagnosing, prognosticating, staging, and otherwise assessing diseases that are reduced to a medium that can be automatically read such as computer readable media (magnetic, optical, and the like). Preferred embodiments can also include instructions for assessing the gene expression profiles in such media. For example, preferred embodiments may comprise a CD ROM having computer instructions for comparing gene expression profiles of the portfolios of genes described above. The preferred embodiments may also have gene expression profiles digitally recorded therein so that they may be compared with gene expression data from patient samples. Alternatively, the profiles can be recorded in different representational format. A graphical recordation is one such format. Clustering algorithms such as those incorporated in "OMNIVIZ" and "TREE VIEW" computer programs mentioned above can best assist in the visualization of such data.

The biological effect of a drug may be a consequence of drug-mediated changes in the rate of transcription or degradation of one or more species of RNA, the rate or extent of translation or post-translational processing of one or more polypeptides, the rate or extent of the degradation of one or more proteins, the inhibition or stimulation of the action or activity of one or more proteins, and so forth. In addition to the preferred FTI's, the preferred drugs include those that modulate the MAPK/ERK signaling pathways, TGF- β , WNT or apoptotic pathways. These include, without limitation, tyrosine kinase

inhibitors, MEK kinase inhibitors, P13K kinase inhibitors, MAP kinase inhibitors, apoptosis modulators and combinations thereof. Exemplary drugs that are most preferred among these are the "GLEEVEC" tyrosine kinase inhibitor of Novartis, U-0126 MAP kinase inhibitor, PD-098059 MAP kinase inhibitor, SB-203580 MAP kinase inhibitor, and antisense, ribozyme, and DNzyme Bcl-XL anti-apoptotics. Examples of other useful drugs include, without limitation, the calanolides of US Patent 6,306,897; the substituted bicyclics of US Patent 6,284,764; the indolines of US Patent 6,133,305; and the antisense oligonucleotides of US Patent 6,271,210.

Pharmaceutically useful compositions comprising the drugs described herein may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the drug. The effective amount of the drug may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration. The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.

The drugs described herein include chemical derivatives of the base molecules of the drug. That is, they may contain additional chemical moieties that are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages defined by routine testing in order to obtain optimal inhibition or activity while minimizing any potential toxicity. In addition, co-administration or sequential administration of other agents may be desirable.

The drugs described herein can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the drugs can be

administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as a modulating agent.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.

The dosage regimen utilizing the compounds or modulators described herein is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular drug employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

The drugs described herein form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and

synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation,
5 starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

For liquid forms the active drug component can be combined in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. Other dispersing agents that may be employed include glycerin and the like. For parenteral administration, sterile suspensions
10 and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.

The compounds or modulators may alternatively be administered parenterally via injection of a formulation consisting of the active ingredient dissolved in an inert liquid carrier. Injection may be either intramuscular, intraluminal, intratracheal, or
15 subcutaneous. The injectable formulation consists of the active ingredient mixed with an appropriate inert liquid carrier. Acceptable liquid carriers include the vegetable oils such as peanut oil, cotton seed oil, sesame oil and the like as well as organic solvents such as solketal, glycerol formal and the like. As an alternative, aqueous parenteral formulations may also be used. The vegetable oils are the preferred liquid carriers. The formulations
20 are prepared by dissolving or suspending the active ingredient in the liquid carrier such that the final formulation contains from 0.005 to 10% by weight of the active ingredient.

All citations herein are hereby incorporated herein by reference. Further, also incorporated by reference is the previously filed US patent applications 60/340,938 filed October 30, 2001; 60/338,997 filed October 30, 2001, 60/340,081 filed October 30,
25 20001, 60/341,012 filed October 30, 2001, 10/283,975 filed on October 30, 2002 and 11/589,660 filed on October 30, 2006, including all references cited therein. The disclosure is further illustrated by the following non-limiting examples.

EXAMPLE 1

Materials and Methods

Clinical Evaluation

In an exemplary example, bone marrow samples are collected from an open label, multicenter, non-comparative phase 2 study investigating the efficacy and safety of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA[®]) in older adults with previously untreated, poor-risk AML.

Sample Collection and Processing

Bone marrow samples were collected from consenting patients before treatment with tipifarnib followed by mononuclear cells preferably being processed on site. Bone marrow aspirates were diluted with PBS and centrifuged with ficoll-diatrizoate (1.077g/ml). Enriched leukemic blood cells were washed twice with PBS, resuspended in FBS with 10% DMSO and immediately frozen at -70°C to -80°C. Total RNA was extracted from cell samples using the Trizol Kit (Qiagen, Santa Clarita, CA). RNA quality may be determined by assessing the presence of ribosomal bands on an Agilent Bioanalyzer. Good quality samples were further processed for microarray analysis. DNA was isolated from the same sample of Trizol-processed bone marrow as per the manufacturer's instructions (Qiagen, Santa Clarita, CA). Samples were assayed for global gene expression, *N-RAS* mutations, and/or qPCR of specific genes (Fig 1). *N-RAS* mutational status

Analysis of activating mutations in *N-RAS* was determined by PCR and RFLP analysis as previously described. End et al. (2001). Exons 1 and 2 of the *N-RAS* gene were simultaneously amplified in a single multiplex reaction and an aliquot was used for a second round of PCR. Resistance to cleavage at natural or primer induced restriction enzyme sites in second-round amplicons indicated the presence of a mutation that had abolished the site at the loci being analyzed. Restriction enzymes for the analysis of specific loci were *Bsl* I (*N-ras* codons 12 and 13), *Msc* I (*N-ras* codon 61, positions 1 and 2), and *Bfa* I (*N-ras* codon 61, position 3). Reactions were digested overnight and PCR products were analyzed on an Agilent Bioanalyzer.

Microarray analysis

Synthesis of cDNA and cRNA were performed according to Affymetrix (Santa Clara, CA) protocols. Since the yield of many samples was low, two rounds of linear amplification were performed as previously described in US Patent Publication No. 20070048782. For hybridization, 11 µg of cRNA were fragmented randomly by
5 incubation at 94°C for 35 min in 40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate, and 30 mM magnesium acetate. Fragmented cRNA was hybridized to U133A arrays at 45°C for 16 h in a rotisserie oven set at 60 rpm. Following hybridization, arrays were washed (with 6x SSPE and 0.5x SSPE containing Triton X-100 (0.005%)), and stained with streptavidin-phycoerythrin (SAPE; Molecular Probes, Eugene, OR). Quantification
10 of bound labeled probe was conducted using the Agilent G2500A GeneArray scanner (Agilent Technologies, Palo Alto, CA).

The total fluorescence intensity for each array was scaled to the uniform value of 600. Chip performance was quantified by calculating a signal to noise ratio (raw average signal/noise). Chips were removed from further analysis if their signal-to-noise ratio was
15 less than 20 or if the present calls on the chip was less than 30%. Genes were only included in further analysis if they were called “present” in at least 10% of the chips. Approximately 12,000 Affymetrix probe sets remained following this cut-off. The quality of the gene expression data were further controlled by identifying outliers based on principal components analysis and by analyzing the normal distributions of the gene
20 intensities (Partek Pro V5.1). The microarray data have been deposited in NCBI's Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>).

Response definitions

Response to tipifarnib was defined as patients who had a complete response (CR), a partial response (PR), or hematological improvement (HI). Briefly, HI was defined as
25 any bone marrow blast count less than 5% or a reduction in bone marrow blasts by at least half. Progressive disease (PD) was defined as either >50% increase in bone marrow or circulating blast % from baseline, or new appearance of circulating blasts (on at least 2 consecutive occasions). Stable disease (SD) was defined as any response not meeting CR, PR, HI, or PD criteria.

Statistical analysis

Receiver Operator Characteristic (ROC) analysis was utilized to test the overall predictive value of individual genes and/or multigene classifiers. The following gene filtering criteria were used to identify genes differentially expressed between responders and patients with progressive disease: Specificity for identifying “responder” with 100% sensitivity $\geq 40\%$, T-test p value (log2 transformed data with unequal variance) < 0.05 , fold change > 2 . The genes that passed these criteria were ranked by AUC (Area under the ROC curve).

To build a classifier the response score was used to calculate each patient's likelihood of responding to tipifarnib therapy. The score was defined as the linear combination of weighted expression signals with the t-statistic as the weight. The threshold was determined from the ROC curve of the training set to ensure 100% sensitivity and the highest specificity. To determine how many genes needed to be included in the predictor, leave-one-out cross validation (LOOCV) was carried out. The response scores for the ‘left-out’ samples based on different numbers of genes were recorded. The performances of the predictors with different numbers of genes were assessed based on misclassification error rate, sensitivity, specificity, p values measuring the separation of Kaplan-Meier curves of the two predicted groups. And the best predictor was selected accordingly.

The Top Scoring Pair (TSP) algorithm was first introduced by Geman et al. (2004). In essence, the algorithm ranks all the gene pairs (genes i and j) based on the absolute difference (D_{ij}) in the frequency of event where gene i has higher expression value than gene j in samples among class C1 to C2. In the cases of there are multiple top scoring pairs (all sharing the same D_{ij}), the top pair by a secondary rank score that measures the magnitude to which inversions of gene expression levels occur from one class to the other within a pair of genes is selected. The top pair with highest frequency of absolute $D_{ij} > 2$ fold in all samples will be selected as candidate pair. The candidate pair was then assessed in an independent testing data set.

Leave-one-out cross validation (LOOCV) was carried out in the training data set to evaluate how the algorithm perform. The performances of the predictors were

assessed based on maximum misclassification error rate. All the statistical analyses were done using R (R Development Core Team, 2006).

Real-Time Quantitative RT-PCR

For each sample, 1 µg of total RNA (as assessed by OD₂₆₀) was reversed
5 transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Samples were then incubated at 25°C for 10 minutes and then 37°C for 30 minutes for optimum RNA conversion. QPCR was performed using the ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA) with all samples run in triplicate.
10 Each reaction contained 5 µl TaqMan® Universal PCR Master Mix containing UNG (Applied Biosystems, Foster City, CA), 4.5 µl of cDNA template and 0.5 µl of 20 x Assay on Demand Gene Expression Assay Mix or 9 pmol of both forward and reverse primer and 2.5 pmol of probe (Applied Biosystems, Foster City, CA), in a total reaction volume of 10 µl. All primer, probe sets were chosen due to the small amplicon size (less
15 than 100 nucleotides) and FAM fluorogenic probes were used. Primers and probes used were *APTX* (product number 4331182 Applied Biosystems) and *RASGRP1* (product number 4351372 Applied Biosystems). The *RASGRP1:APTX* expression ratio was calculated by normalizing the raw Ct values by subtracting the mean Ct from the sample set, dividing by the standard deviation, and then calculating the difference of the
20 normalized Ct values of each gene (*APTX* – *RASGRP1*).

Results

This study examined gene expression profiles of leukemic bone marrow samples from patients enrolled in a Phase 2 clinical trial of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myelogenous
25 leukemia. Lancet et al. (2006). Bone marrow from 67 patients was collected before treatment with tipifarnib and leukemic myeloid cells were enriched by Ficoll-density centrifugation (Table 1). Good quality total RNA from 13 responders (9 CR, 4 HI), 8 stable disease and 13 progressive disease patients was amplified, labeled, and hybridized to the Affymetrix U133A GeneChip. A total of 30 samples were evaluated by qPCR for
30 validation of specific genes and 32 samples were evaluated for *N-RAS* mutational status.

Table 1. Comparison of profiled patients.

Parameter	All treated patients	PGx profiled patients
Total patients, n	158	67
microarray assay, n		34
qPCR assay, n		30
N-Ras assay, n		32
N-Ras mutation, n (%)		11 (34)
median age, y (range)	74 (34-85)	73 (63-85)
sex, n male (%)	95 (60)	41 (61)
Prior MDS, yes (%)	119 (75)	48 (72)
CR, no. (%)	22 (14)	14 (21)
PR, no. (%)	3 (2)	1 (2)
HI, no. (%)	12 (8)	7 (10)
SD, no. (%)	50 (32)	15 (22)
PD, no. (%)	58 (37)	30 (44)
NE, no. (%)	13 (8)	0 (0)

CR = complete response; PR = partial response; HI = hematological improvement, SD = stable disease, PD = progressive disease, NE = not evaluable; PGx = pharmacogenomics

Ras mutational status and patient outcome.

- 5 DNA from the bone marrow of 32 AML patients was screened for *N-Ras* activating mutations (codons 12, 13, 61). Thirty-four percent (11/32) of patients exhibited *N-Ras* mutations with one patient having mutations at multiple codons (Table 2). There was no statistically significant correlation between *N-RAS* mutational status and response to tipifarnib or overall survival.

10 **Table 2.**

SUBJID	RESPONSE	N-Ras Mutation	OS	Alive	Microarray	qPCR	SEX	AGE	Prior MDS
100101	HI	ND	378	NO	ND	YES	MALE	68	NO
100104	PD	ND	728	NO	YES	YES	FEMALE	63	NO
100109	PD	ND	68	NO	YES	YES	FEMALE	81	NO
100110	CR	ND	983	YES	YES	YES	FEMALE	74	NO
100112	PD	ND	169	NO	ND	YES	FEMALE	69	YES
100113	CR	ND	211	NO	ND	YES	MALE	82	YES
100116	PD	ND	14	NO	ND	YES	FEMALE	72	YES
100121	SD	ND	252	NO	YES	ND	MALE	72	YES
100204	SD	N-12	493	NO	ND	ND	FEMALE	69	YES
100205	PD	WT	754	NO	YES	ND	MALE	74	YES
100208	PD	WT	29	NO	YES	ND	MALE	76	YES
100209	PD	N61(1,2)	209	NO	YES	ND	MALE	73	YES
100210	PD	N-12, N-13	654	NO	YES	ND	MALE	68	YES
100212	SD	N-12	1200	YES	ND	ND	MALE	70	YES
100213	CR	WT	257	NO	YES	ND	FEMALE	81	YES
100214	CR	N-13	395	NO	ND	ND	FEMALE	73	YES
100215	SD	WT	54	NO	ND	ND	MALE	82	NO
100216	SD	N-13	116	NO	ND	ND	MALE	77	YES

100302	PD	N-12	48	NO	YES	ND	FEMALE	73	NO
100307	HI	WT	179	NO	YES	ND	MALE	68	YES
100310	SD	WT	242	NO	ND	ND	FEMALE	76	YES
100316	SD	WT	273	NO	ND	ND	FEMALE	66	NO
100317	PD	WT	39	NO	ND	ND	MALE	76	NO
100319	SD	WT	233	NO	YES	ND	MALE	71	NO
100320	HI	WT	374	NO	ND	ND	FEMALE	78	NO
100322	CR	WT	237	YES	YES	ND	MALE	73	YES
100324	HI	WT	248	NO	YES	ND	MALE	85	YES
100330	HI	N-12	153	NO	YES	ND	FEMALE	67	NO
100333	SD	N-12	364	NO	YES	ND	MALE	65	YES
100336	CR	N-12	67	NO	YES	ND	MALE	80	YES
100337	PD	WT	38	NO	ND	ND	MALE	72	YES
100338	PD	N-12	8	NO	YES	ND	MALE	78	NO
100339	PD	WT	25	NO	YES	ND	MALE	75	NO
100340	SD	WT	32	NO	ND	ND	FEMALE	83	NO
100341	CR	WT	433	NO	YES	ND	MALE	67	YES
100604	SD	WT	64	NO	YES	ND	MALE	63	YES
100605	PD	WT	74	NO	ND	ND	MALE	67	YES
101008	CR	WT	548	NO	YES	ND	MALE	82	NO
101021	CR	ND	991	YES	YES	YES	FEMALE	69	YES
101025	CR	ND	735	YES	ND	YES	MALE	70	YES
101029	PD	ND	64	NO	ND	YES	MALE	70	YES
101038	SD	ND	151	NO	YES	ND	FEMALE	75	YES
101039	PD	ND	50	NO	ND	YES	FEMALE	85	YES
101043	SD	ND	200	NO	YES	ND	FEMALE	79	YES
101046	PD	ND	53	NO	YES	YES	FEMALE	66	YES
101049	CR	WT	564	NO	YES	ND	MALE	65	YES
101057	CR	WT	386	NO	YES	ND	MALE	85	YES
101067	PD	ND	88	NO	ND	YES	FEMALE	76	YES
101069	PD	ND	94	NO	ND	YES	MALE	81	YES
101075	HI	ND	659	YES	YES	YES	MALE	71	YES
101077	SD	ND	574	YES	YES	ND	FEMALE	75	YES
101078	PD	ND	190	NO	ND	YES	FEMALE	77	NO
101079	PD	ND	429	NO	ND	YES	FEMALE	70	YES
101083	PD	ND	71	NO	ND	YES	MALE	73	YES
101091	CR	ND	671	YES	ND	YES	MALE	71	YES
101092	PD	ND	136	NO	ND	YES	FEMALE	69	YES
101094	HI	ND	579	YES	ND	YES	MALE	65	YES
101095	PD	ND	108	NO	YES	YES	MALE	82	YES
101096	CR	ND	390	YES	ND	YES	MALE	69	YES
101101	PD	ND	91	NO	ND	YES	MALE	69	YES
101102	PD	ND	76	NO	YES	YES	MALE	69	YES
101103	PD	ND	29	NO	ND	YES	FEMALE	80	NO
101108	PR	ND	123	NO	NO	YES	MALE	70	YES
101109	SD	ND	656	YES	YES	ND	MALE	68	YES
101114	PD	ND	69	NO	YES	YES	MALE	72	YES
101121	PD	ND	43	NO	ND	YES	MALE	78	NO
101122	PD	ND	44	NO	ND	YES	FEMALE	80	NO

ND = not determined; WT = wildtype; CR = complete response; PR = partial response; HI = hematological improvement, SD = stable disease, PD = progressive disease, OS = Overall survival.

Identification of predictive genes from the newly diagnosed AML cohort

5 The next aim was to identify genes predictive of response to tipifarnib in the newly diagnosed AML population. To this end discovery experiments were performed in the 13 responders (9 CR and 4 HI) and 13 patients with progressive disease. Patients with stable disease were not utilized in this analysis since these patients cannot be clearly defined as either responders or non-responders. Using the same approach as was utilized
10 for identifying markers for relapsed and refractory AML (20070048782) we identified 45 probesets (corresponding to 38 unique genes) that were predictive of response (Table 3). The selection criteria aimed at identifying genes that would predict responders with a high sensitivity (approaching 100%) with a specificity cut-off of 40% and a mean gene expression difference of at least two-fold. The genes were ranked based on the area
15 under the curve (AUC) defined from a receiver operator characteristic (ROC) analysis of the training set. This value represents the overall predictive value of the gene with an AUC of 1.0 indicating perfect classification. Each gene was first tested on the training set using a LOOCV method. The top gene, the RAS guanyl-releasing protein 1 (*RASGRP1*), showed an AUC of 0.95.

20

Table 3. 45 probesets predictive of response to tipifarnib in newly diagnosed AML

Probe Set ID	Gene Symbol	Gene Title	pvalue	spec	tstat	FC	AUC
205590_at	RASGRP1	RAS guanyl releasing protein 1	2.64E-06	0.54	6.40	4.01	0.95
217028_at	CXCR4	chemokine (C-X-C motif) receptor 4	4.41E-05	0.69	5.08	2.35	0.92
206687_s_at	PTPN6	protein tyrosine phosphatase, non-receptor type 6	8.23E-05	0.77	-4.75	-2.15	0.91
210439_at	ICOS	inducible T-cell co-stimulator	1.27E-04	0.77	4.56	3.81	0.91
206641_at	TNFRSF17	tumor necrosis factor receptor superfamily, member 17	3.79E-02	0.62	2.24	2.55	0.91
213539_at	CD3D	CD3d molecule, delta (CD3-TCR complex)	1.75E-04	0.69	4.63	2.82	0.91
208018_s_at	HCK	hemopoietic cell kinase	2.62E-04	0.62	-4.28	-3.14	0.90
203063_at	PPM1F	protein phosphatase 1F (PP2C domain containing)	3.66E-04	0.85	-4.17	-2.31	0.90
208130_s_at	TBXAS1	thromboxane A synthase 1	2.70E-04	0.46	-4.26	-2.51	0.89
216834_at	RGS1	regulator of G-protein signalling 1	3.90E-04	0.62	4.16	3.48	0.87
213388_at	PDE4DIP	phosphodiesterase 4D interacting protein (myomegalin)	1.47E-03	0.54	-3.64	-2.01	0.86
38487_at	STAB1	stabilin 1	7.95E-04	0.54	-3.87	-2.45	0.86
210982_s_at	HLA-DRA	major histocompatibility complex, class II, DR alpha	4.23E-03	0.69	-3.25	-3.07	0.85
210321_at	GZMH	granzyme H (cathepsin G-like 2, protein h-CCPX)	1.64E-03	0.54	3.55	2.83	0.85
217147_s_at	TRAT1	T cell receptor associated transmembrane adaptor 1	1.19E-03	0.54	3.72	2.82	0.85
206298_at	ARHGAP22	Rho GTPase activating protein 22	7.89E-04	0.62	-3.88	-2.19	0.85
202990_at	PYGL	phosphorylase, glycogen; liver	1.95E-03	0.46	-3.50	-2.01	0.85
221671_x_at	IGKC	immunoglobulin kappa constant	1.62E-03	0.46	3.56	3.10	0.85
221651_x_at	IGKC	immunoglobulin kappa constant	1.65E-03	0.46	3.57	2.92	0.85
207651_at	GPR171	G protein-coupled receptor 171	1.13E-03	0.62	3.70	3.01	0.85
202988_s_at	RGS1	regulator of G-protein signalling 1	1.48E-03	0.54	3.59	2.95	0.84
213418_at	HSPA6	heat shock 70kDa protein 6	1.63E-02	0.62	-2.61	-2.34	0.83
209901_x_at	AIF1	allograft inflammatory factor 1	3.52E-03	0.54	-3.24	-2.48	0.83
205488_at	GZMA	granzyme A	4.43E-03	0.46	3.18	2.75	0.83
217022_s_at	IGHA1	immunoglobulin heavy constant alpha 1	3.43E-03	0.69	3.36	2.56	0.83
207339_s_at	LTB	lymphotoxin beta (TNF superfamily, member 3)	1.34E-03	0.46	3.65	2.40	0.83
206337_at	CCR7	chemokine (C-C motif) receptor 7	1.14E-03	0.54	3.71	2.08	0.83
208894_at	HLA-DRA	major histocompatibility complex, class II, DR alpha	6.14E-03	0.46	-3.05	-2.58	0.82
39729_at	PRDX2	peroxiredoxin 2	5.81E-03	0.54	3.05	2.13	0.82
209500_x_at	TNFSF13	tumor necrosis factor (ligand) superfamily, member 13	1.23E-03	0.46	-3.68	-2.02	0.82
214677_x_at	IGL@	immunoglobulin lambda locus	4.69E-03	0.46	3.17	2.86	0.82
210314_x_at	TNFSF13	tumor necrosis factor (ligand) superfamily, member 13	3.48E-03	0.46	-3.24	-2.05	0.81
209138_x_at	IGL@	Immunoglobulin lambda locus	4.17E-03	0.54	3.17	3.41	0.80
207831_x_at	DHPS	deoxyhypusine synthase	1.09E-02	0.62	-2.77	-2.05	0.80
215121_x_at	IGL@	immunoglobulin lambda locus	1.20E-02	0.46	2.72	4.42	0.79
215946_x_at	CTA-246H3.1	similar to omega protein	1.10E-02	0.46	2.76	2.46	0.79
204069_at	MEIS1	Meis1, myeloid ecotropic viral integration site 1 homolog	1.01E-02	0.62	-2.89	-2.14	0.78
204698_at	ISG20	interferon stimulated exonuclease gene 20kDa	6.93E-03	0.46	2.95	2.39	0.78
209906_at	C3AR1	complement component 3a receptor 1	1.49E-02	0.54	-2.65	-2.05	0.77
205608_s_at	ANGPT1	angiopoietin 1	6.40E-03	0.46	-3.11	-2.18	0.76
205927_s_at	CTSE	cathepsin E	2.02E-02	0.46	2.55	2.05	0.76
215051_x_at	AIF1	allograft inflammatory factor 1	1.54E-02	0.62	-2.62	-2.03	0.76
205609_at	ANGPT1	angiopoietin 1	4.12E-02	0.54	-2.20	-3.11	0.73
202890_at	MAP7	microtubule-associated protein 7	3.30E-02	0.62	-2.30	-2.31	0.73
203485_at	RTN1	reticulon 1	2.60E-02	0.54	-2.40	-2.29	0.72

Spec = specificity, FC = fold change, AUC = area under the curve of Receiver Operator Characteristic Analysis, negative t-statistic indicates gene is down in responders.

Whether increasing the number of genes in the classifier improved its predictive value was also examined. Using the LOOCV approach and then plotting sensitivity, specificity, and overall error rate of each classifier, the top gene alone was found to provide the best predictive value (data not shown). Adding genes to the classifier in a linear fashion did not improve its predictive value. Using a cutoff that biases for high sensitivity, the LOOCV demonstrated that the expression of the *RASGRP1* gene allowed for a NPV 88.9%, and a PPV of 70.6%, with an overall predictive accuracy of 76.9% (Fig 1A). In addition, Kaplan Meier analysis showed a significant difference in median overall survival of the responders (386 days) and those with progressive disease (68 days) (Fig 1B). Over expression of this single gene therefore predicted response to tipifarnib in newly diagnosed AML with a high negative predictive value.

15

Identification of a Top Scoring Pair classifier

The predictive value of *RASGRP1* was not improved if additional genes were added to the classifier using a linear approach. An alternative gene selection algorithm was utilized to select genes that would improve the predictive value of *RASGRP1* alone. To this end the Top Scoring Pair (TSP) algorithm was utilized to identify the best pair of genes that would provide the greatest predictive accuracy. Geman et al. (2004). This approach was utilized to exploit the greatest difference in expression between two genes and may be useful when aiming to develop a qPCR based diagnostic assay. The TSP from the training set was *RASGRP1* and aprataxin (*APTX*). *RASGRP1* and *APTX* were over- and under-expressed in responders, respectively. A robust LOOCV showed that this top scoring pair (TSP) provided 85.7% NPV and 91.7% PPV in the training set of samples with an overall error rate of only 8% (Fig 2A). The difference in overall survival between predicted responders and non-responders was 357 days (Fig 2B). These data demonstrate that the model-building algorithm has a low associated prediction error rate.

30

Validation of the *RASGRP1:APTX* classifier in an independent set of relapsed or refractory AML

External validation of the TSP classifier was performed in an independent microarray dataset comprising of 54 relapsed/refractory AML patient samples. A
5 diagnostic assay that predicts likely response to a cancer therapy should have a high sensitivity (and negative predictive value) since it is important to capture as many potential responders as possible. Therefore, to define an appropriate cutoff for testing the TSP classifier the need to obtain a high sensitivity of predicting responders while maintaining an acceptable level of specificity was considered. In the training set, the
10 level of specificity that could be achieved ranged from approximately 30% to 100% when the sensitivity was set at 100% to 80%, respectively. To ensure the classifier would predict as many responders as possible a conservative cutoff that provided a specificity of approximately 60% in the training set was tested. When this cutoff was applied to the independent testing set of relapsed/refractory AML, the *RASGRP1:APTX* gene classifier
15 stratified responders with 92% NPV and 27.6% PPV (compared to 18.5% prevalence) (Fig 3C). The associated odds ratio for being a responder was 4.38. While this was similar to the predictive accuracy of *RASGRP1* alone, the application of the TSP classifier demonstrated a better NPV and an improved difference in overall survival of 98 days between predicted responders and progressors (Fig 3A), compared to only 56 days
20 for *RASGRP1* (Fig 4).

QPCR validation of the *RASGRP1:APTX* expression ratio

A two-gene expression ratio allows the use of a more clinically relevant qPCR detection system. Thirty samples (20 PD, 6 CR, 3 HI and 1 PR) provided enough total
25 RNA for qPCR. Therefore, the *RASGRP1:APTX* gene expression ratio was evaluated as a predictor of response to tipifarnib using TaqMan® qPCR in these 30 samples (10 responders, 20 progressive disease) from the newly diagnosed AML clinical study. Nine of these samples had been assayed on the microarray platform, however 21 had not been utilized in the discovery set due to poor quality RNA. Therefore, two thirds of this test
30 set was comprised of completely independent samples.

Evaluation of the 9 samples indicated there was good correlation ($r = 0.74$) of the *RASGRP1:APTX* expression ratio between the two platforms (Fig 6). Using a cut-point of 0, the two-gene classifier correctly predicted the treatment outcome in 20 of the 30 patients with PPV and NPV of 50% and 81%, respectively (Fig 3B). The median overall survival of the predicted resistant patients was 82 days while those classified as responders had a median value of 295 days (Fig 3C).

The *RASGRP1:APTX* classifier does not have prognostic utility independent of FTI treatment

The two-gene expression ratio was tested in an independent microarray dataset of 116 AML patients treated with chemotherapeutic regimes. When the *RASGRP1:APTX* classifier was applied to this set of patients, utilizing a similar cut-off as for the tipifarnib-treated population, no significant separation in overall survival was seen (Fig 5). Nor were significant survival differences observed when a range of other cut-offs was utilized (Table 4). This indicated that the *RASGRP1:APTX* classifier specifically stratifies patients who have been treated with tipifarnib and is not relevant to non-FTIs. On the other hand when the prognostic signature was applied to our set of relapsed and refractory AML patients there was a clear stratification in terms of overall survival.

Table 4.

cutoff	p value	Responders median OS	Progressors median OS	No. Responders	No. Progressors
0.5	0.956	336	414	13	103
0.6	0.342	672	374	24	92
0.7	0.266	511	335	34	82
0.8	0.269	511	326	47	69
0.9	0.101	540	316	57	59
1	0.215	483	326	64	52
2	0.795	374	570	94	22
3	0.209	346	909	104	12

OS = overall survival

EXAMPLE 2

This example describes an improved RT-PCR assay suitable for applying the two-gene assay to FTI combination therapy. During the analytical assay development Taqman assays for 3 markers: *RASGRP1* (guanine nucleotide exchange factor that activates *RAS*), *APTX* (aprataxin involved in DNA excision repair) and *HMBS* (used as an

internal control) were designed. HMBS could be used as a control in an embodiment or be dispensed with in other embodiments. Sequences of Taqman primer probe sets and their amplicons are listed above in the Summary section and in the Sequences Section of this disclosure. Namely, for APTX - SEQ # 3-4 and 2, *RASGRP1* primer probe set SEQ #56 and 1; and *HMBS* - SEQ # 7-9.

Quantitative RT-PCR assays were developed and optimized using ABI-7500 platform to assess the 2-gene ratio performance with FAM-labeled *RASGRP1*, Gold 540-*APT*X and Cy5-*HMBS* in a single-tube triplex format. JY cellular RNA and Universal RNA (Stratagene) were used as external normalization.

10 $RASGRP1:APT$ X ratio = $2^{-((A-B)-(C-D))}$

Where A: Sample *RASGRP1* Ct value

B: JY (or Universal) RNA (+) *RasGRP1* Ct value

C: Sample *APT*X Ct Value

D: JY (or Universal) RNA (+) *APT*X Ct Value

15 Other sources of cellular RNA could be substituted provided the assay parameters, in particular, the threshold, are recalculated for the particular cellular RNA employed for external normalization. The reference RNA used for external normalization is preferably from a cell line grown under defined conditions and that is relatively non-responsive to FTIs. Without being bound by theory, a suitable reference
20 RNA may be derived from a cell line that is neutral in its response to FTI. Such a reference cell line may be developed from patients testing in the threshold region based on the two-gene assay, but who actually are non-responsive to FTI treatment. Thus, without being bound by theory, such patients are a likely source for developing an improved reference RNA for the two-gene ratio test. One possible method for
25 developing and evaluating a cell line may be to select a cell line that, when used as an external control in the two-gene assay, tends to increase the threshold. This criteria is reasonable because such a cell line(s) will damp (due to a possible correlation in its two-gene response and that being measured) the measured two-gene ratio the least. Alternatively, the external control may be selected using a defined combination of *APT*X
30 and *RASGRP1* RNA to allow for absolute quantitation or using AUC to maximize discrimination between responders and non-responders. The choice of the external

control is not the only source of variability in the threshold employed in the two-gene assay.

Two RT-PCR formats were developed and their performance assessed using a standard curve analysis. Both formats are demonstrably equivalent in performance with a high Pearson correlation using both raw C_t s of 3 markers and derived from them 2-gene ratio values ($R^2=1 - 0.93$, $P<0.000$; Table 5).

Table 5. Pearson Correlation between RUO and GMP RT-PCR assays

RUO vs GMP RT-PCR format	
RasGRP1, Mean C_t	0.97
APTX, Mean C_t	0.99
HMBS, Mean C_t	1.00
Ratio normalized to JY control RNA	0.93

RUO format uses a commercially available RNA-to- C_t One Step RT-PCR Kit distributed by INVITROGEN[®] (Cat. No.4392938). This format has a 20 μ l reaction volume with 50 ng total RNA input according to the manufacturer's instructions.

GMP format is based on the VERIDEX[®] BLN RT-PCR Kit components (GeneSearch[®] Breast Lymph Node (BLN) Test Kit, IVD, Cat #2900004) with GeneSearch[®] BLN Enzyme Mix, IVD, P/N 7700040 and BLN Base Master Mix, P/N 7700031 used for preparation of RT-PCR master mix. The GMP format has a 25 μ l reaction with 50 ng RNA input using an optimized RT step described next.

RT-PCR multiplexed protocol in a GMP format

50ng of total RNA was used as a target input in a triplex qRT-PCR which was carried out on an Applied Biosystems Prism 7500 Sequence Detection System in a 25 μ L reaction. RNA samples (including normalization control RNAs) were thawed on ice and diluted to 10 ng/ μ l. The qRT-PCR was carried out using reagents from the VERIDEX[®] BLN RT-PCR Kit (GeneSearch[®] Breast Lymph Node (BLN) Test Kit, IVD, Cat #2900004): GeneSearch[®] BLN Enzyme Mix, IVD, P/N 7700040 and BLN Base Master Mix, P/N 7700031.

25X probe-primer master mix was prepared comprising: 400 nM SEQ No. 1 and 2, respectively, and 200 nM FAM-labeled RasGRP1 (SEQ No.10); 400 nM SEQ No. 3 and 4, and 200 nM Gold 540-APTX (SEQ No. 11), and 400 nM of SEQ No. 8 and 9 and 200 nM Cy5-HMBS (SEQ No. 12) as summarized in Table 6.

5

Table 6. 25X Probe/Primer Mix

3plex-1 (25X)	Sequence	Stock to Add/rxn	500	Final Conc.
Marker				in 25 μ L
RASGRP1	RASGRP1 SEQ No. 1	0.10	50.00	0.4 μ M
	RASGRP1 SEQ No. 2	0.10	50.00	0.4 μ M
	RASGRP1 (Fam) SEQ No. 10	0.05	25.00	0.2 μ M
APTX	APTX SEQ No. 3	0.10	50.00	0.4 μ M
	APTX SEQ No. 4	0.10	50.00	0.4 μ M
	APTX SEQ No. 11 (Gold)	0.05	25.00	0.2 μ M
HMBS	HMBS SEQ No. 8	0.10	50.00	0.4 μ M
	HMBS SEQ No. 9	0.10	50.00	0.4 μ M
	HMBS SEQ No. 12	0.05	25.00	0.2 μ M
	idTe	0.25	125.00	
	Total	1.00	500.00	

Each reaction consisted of 9 μ L of BLN Base Master Mix, 10 μ L of 2.5X BLN Enzyme mix and 1 μ L of 25X primer/probe mix. The primer/probe mix had a final concentration of 400nM of forward and reverse primers and 200 nM of fluorescent probes for each marker. 5 μ L of total RNA from patient samples or normalization controls (Universal or JY RNA) was added to 20 μ L of RT-PC master mix.

A threshold/cutoff of 5.2 was determined based on JY cellular RNA used as an external normalization control.

The qRT-PCR assays were carried out using the following cycling parameters: 1 min at 95°C for denaturation step; 30 minutes at 58°C (RT reaction); 5% ramp to 70 °C

and incubation for 2 min followed by 40 cycles at 95°C for 15 seconds (denaturation) and 60°C for 1 minute (annealing/extension). This optimization of probe-primer concentrations of the GMP RT-PCR format in a single-tube multiplexed set-up attained a robust and sensitive detection of RNA targets from both bone marrow and peripheral blood samples at the level of 0.6 ng with Ct values around 31, i.e. in a low variability and highly reproducibility range of Cts (Figure 3). This reaction format is suitable for commercialization of the test, being based on the GMP grade reagents formulated and manufactured for the FDA-approved BLN kit, such as Tth Polymerase (enzyme mix) and Base master mix. Some details for the Master Mix based protocol are provided in Table 7.

Table 7. Master Mix based protocol

Reagents	
BLN Enzyme mix, BLN Master Mix	
Prepare bulk RT-PCR Master Mix	
Master Mix	
RT-PCR	1 rxn. (μL)
BLN Base Master Mix	9
2.5X BLN Enzyme Mix	10
25X Primer/Probe mix	1
Total	20
Prepare bulk RT-PCR Mix by multiplying reagent volumes on the table by the number of	
Samples plus extra 10%	
Add 20 μL Master Mix in each well of a 96-well plate	
Add 5 μL diluted RNA sample to appropriate well	
Add 5 μL of Universal RNA (external control) and (Nf water—No Target Control)	
Seal the plate. Vortex briefly and centrifuge at 1500 rpm for 1 min.	
Place in ABI 7500(1)	

Data Analysis

1. Inclusion Criteria

The cycle threshold (C_t) values obtained from ABI7500 data output files were used for data analysis. C_t Cutoffs for “No Test” for each Marker were selected as

5 follows:

HMBS (internal control maker) C_t should not be greater than 30;

RASGRP1 C_t - not greater than 35 and

APTX C_t - not greater than 35.

10 If a sample had any one of the two markers, *RASGRP1* or *APTX*, above the C_t cutoff level, it was considered as “No Test” (excluded from the data analysis). Results presented in Table 8 demonstrate equivalency between singlex and triplex (single-tube) formats of RT-PCR set-up when comparing slope values and PCR efficiency. Table 9 presents further improvements by extending RT step to 30 minutes.

15

Table 8. Performance of Singlex vs. Triplex RT-PCR formats				
Triplex RT-PCR	PCR QC	RASGRP1-Fam	APTX-Gold	HMBS-Cy5
	Slope	-3.6	-3.6	-3.6
	Y-Intercept	29.5	29.6	29.5
	Efficiency	91%	90%	91%
Singlex RT-PCR in 3 channels	Slope	-3.5	-3.6	-3.6
	Y-Intercept	30.0	29.8	29.6
	Efficiency	92%	89%	89%

Table 9. Triplex RT-PCR Performance Optimization				
30 min RT, Primers-400nM, Probes 200nM				
Target ng input	Marker	Average Ct	PCR Efficiency	
100	RasGRP1-Fam	24.0	Slope	-3.4
50		25.1	Intercept	30.8
25		25.9	Efficiency	95%

12.5		26.9		
6.25		28.2		
gDNA(8ng)		Undetermined		
NTC		Undetermined		
100	APTX-Gold	23.7	Slope	-3.3
50		24.7	Intercept	30.2
25		25.6	Efficiency	102%
12.5		26.5		
6.25		27.7		
gDNA(8ng)		Undetermined		
NTC		Undetermined		
100	HMBS-Cy5	22.6	Slope	-3.3
50		23.5	Intercept	29.1
25		24.4	Efficiency	100%
12.5		25.4		
6.25		26.7		
gDNA(8ng)		35.8		
NTC		Undetermined		

Using GMP RT-PCR format, Universal RNA (from AGILENT™) and JY RNA controls (from in-house cultured cell line) were run in RT-PCR with 37 patient samples from Phase 2 T+E study. This analysis was later repeated with 40 patient samples. Both analysis, based on the outcome of ROC curve analysis, are presented in Table 10, to show that the assay performance is equivalent when using JY or Universal RNA controls for raw C_t normalization with an adjustment to the threshold.

The use of Universal RNA as the external control resulted in a threshold of 7.3 compared to a threshold of 5.2 when JY RNA was used as the external control. In these threshold determinations, the calculations treated CR as the Response criteria—with all other response types treated as non-responsive.

Table 10. ROC Curve Analysis: CR vs. NR for TthPol GMP RT-PCR format									
Normalization Control	AUC	SE	95% CI	Cutoff by ROC analysis	Sensitivity	95% CI	Specificity	95% CI	Sample number
JY RNA (37 patient analysis)	0.8	0.97	0.629 to 0.908	>5.2	66.67	30.1 to 92.1	92.86	76.5 to 98.9	CR=9 NR=28
Universal RNA (37 patient analysis)	0.8	0.97	0.629 to 0.908	>5.2	66.67	30.1 to 92.1	92.86	76.5 to 98.9	CR=9 NR=28
JY RNA (40 patient analysis)	0.8	0.0881	0.636 to 0.904	>5.2	63.64	30.9 to 88.8	93.1	77.2 to 99.0	CR=11 NR=29
Universal RNA (40 patient analysis)	0.8	0.0881	0.636 to 0.904	>7.3	63.64	30.9 to 88.8	93.1	77.2 to 99.0	CR=11 NR=29

Although the threshold in the 2-gene assay is dimensionless (being the ratio of RASGRP1 and APTX), without being bound by theory, it is believed that the threshold value may depend on the standards conditions and the reagents used. Therefore, it is preferable to specify the threshold relative to a performance based criterion, such as a ROC curve based criterion. Thus, the threshold/cutoff may be adjusted to meet other requirements such as keeping the AUC value constant with a change in the external control. In this case, using Universal RNA instead of JY RNA as the external control resulted in a higher threshold/cutoff of 7.3 with AUC remaining unchanged.

EXAMPLE 3

This example shows the two-gene assay is effective in newly diagnosed AML patients. The 2-gene response predictive assay was tested first on leukemic blasts from a subset of 84 newly diagnosed AML patients enrolled in Phase 1 dosing study of tipifarnib and etoposide using the technical RT-PCR protocol described in Blood 2008, 111:2589. The clinical plan of Phase 1 trial is described in Blood 2009, 113:4841.

Briefly, fifty-one (51) unpublished evaluable patient samples from this study were analyzed for a preliminary assessment of the performance of the 2-gene assay. Table 11 summarizes the results using a threshold of 5 with RR standing for the response rate with responders exhibiting CR or PR, PPV for positive predictive value and NPV for the negative predictive value. 13 out of 51 patients responded for an RR of about 0.25. Among those who exceeded the threshold of 5 of the two-gene assay, half (9 out of 18) responded resulting in a PPV of about 0.5. Of the patients who did not exceed the threshold, 29 out of 33 did not respond leading to a NPV of 0.88.

Table 11. Results of the two-gene assay on 51 patients						
	CR/PR	Remainder	Total		Measure	Measure Value
>5	9	9	18		RR	0.25
5<	4	29	33		PPV	0.5
Total	13	38	51		NPV	0.88

Compare RUO and GMP RT-PCR Formats

Using both RUO and optimized GMP RT-PCR formats gene expression profiles from 33 bone marrow samples from newly diagnosed AML patients evaluable for clinical response were analyzed. One patient sample (HI) from the RUO RT-PCR data set didn't meet analysis inclusion criteria, thus was excluded from both data sets. Patient annotations by best response are presented in Table 12.

Table 12 Breakdown of Responders and Non-responders	
Best Response	Number of Patients
PD	17
SD	3
CR	7
PR	4
HI	1
Total Evaluable Patients	32

At a later date corresponding, the 33 patients were analyzed again and were found to have 7 complete remission (CR), 4 HI, 3 PR, 7 PD and 11 SD cases (Table 13). When using CR as response criteria, 7 patients were classified as Responders and 25 as Non-responders while when using CR/PR/HI as response criteria, 12 patients were classified as Responders and 20 as Non-responders.

Table 13 Breakdown of Responders and Non-responders	
Best Response	Number of Patients
PD	7
SD	11
CR	7
PR	3
HI	4
Total Evaluable Patients	32

A preliminary statistical analysis to evaluate a possible cutoff value separating 'normal' (Responders, R) from 'abnormal' (Non-Responders, NR) test results was carried out with responders being patients exhibiting CR, PR or HI. A ROC curve analysis for both RT-PCR formats indicated almost equivalent assay performance with AUC value of the 2-gene ratio equal to 71% (Table 14). When using JY RNA as a normalization

control the cutoff of 4.7 was determined for the RUO protocol and 5.2 - for the GMP format based on the ROC curve analysis algorithm. Without being bound by theory, the difference in the thresholds and other parameters based on the format employed is believed to be, in part, due to the specificity or efficiency of the RT-PCR procedure and statistical fluctuations.

Table 14. Comparison of RUO and GMP formats

Table 14. Comparison of RUO and GMP formats								
RT-PCR FORMAT	2-Gene Ratio Cutoff	Sensitivity	95% CI	Specificity	95% CI	AUC	NPV	PPV
ABI, RUO	4.7	50%	21.2 -78.8	90%	68.3 to 98.5	0.71	74%	67%
VRX, GMP	5.2	50%	21.2 -78.8	95%	75.1 to 99.2	0.71	76%	86%

As in the case of the data presented in Tables 12 and 13, at the later date analysis, which treated responders as patients exhibiting complete remission (CR) only—PR and HI patients were included in the group of non-responders, led to the results in Table 15, which lead to thresholds of 5.1 corresponding to the RUO protocol and 5.2 – corresponding to the GMP format based on the ROC curve analysis algorithm.

Table 15. Comparison of RUO and GMP formats								
RT-PCR Format	2-Gene Ratio Cutoff	Sensitivity, %	95% CI	Specificity, %	95% CI	AUC	NPV, %	PPV, %
ABI, RUO	5.1	85.7	42.2-97.6	80	59.3-93.1	0.83	95	55
VRX, GMP	5.2	71.4	29.3-95.5	92	73.9-98.8	0.83	92	71

When using a cutoff value of 5.2 for the GMP RT-PCR data set the overall response rate (for patients exhibiting CR or PR or HI) increased from 38% (ORR) to 86% (PPV) with a negative predictive value of 76% (Table 16) using JY RNA . In other

5 words, 86% of the patients classified as responders by the two-gene assay actually responded, which is an improvement. This outcome is comparable to the 70% response expected from induction therapy in younger patients. In other words, 86% (6 out of seven patients) of those exhibiting a 2-gene ratio value of greater than 5.2 in the GMP RT-PCR format assay responded to treatment with a combination of tipifarnib and

10 etoposide (which corresponds to a PPV of 86%). In contrast, 24% (six out of twenty-five patients) with a 2-gene ratio value of less than or equal to 5.2 responded to treatment with a combination of tipifarnib and etoposide, but were not detected with the 2-gene test. It should be noted that the threshold/cutoff may be adjusted to meet other requirements such as keeping the AUC value constant with a change in the external control. In this

15 case, using Universal RNA instead of JY RNA as the external control resulted in a higher threshold/cutoff of about 8 (from about 5).

A later analysis treating responders as only exhibiting complete recovery led to

Table 17. Results using the GMP format with Responders defined by CR/PR/Hi								
2-Gene Ratio Cutoff	Responder R	Non- Responder NR	Total	PPV	NPV	ORR	Sens	Spec
>5.2	5	2	7	71%				
≤5.2	2	23	25		92%			
	7	25	32			22%	71.4%	92%

the results in Table 17 showing superior NPV and higher sensitivity with comparable specificity.

5

The Kaplan-Meier curve analysis with Hazard Ratio (HR) of 2.3 indicated a positive trend in favor of utility of a 2-gene ratio assay in predicting response between R and NR to the combination of tipifarnib and etoposide in elderly newly diagnosed AML patients (Figures 8 and 13—the two differ in the definitions used for identifying responders). Based on the equivalency of the assay performance characteristics the GMP format was pursued for further development as a companion diagnostic assay.

10

Table 16. Results using the GMP format with Responders defined by CR/PR/Hi								
2-Gene Ratio Cutoff	Responder R	Non- Responder NR	Total	PPV	NPV	ORR	Spec	Sens
>5.2	6	1	7	86%				
≤5.2	6	19	25		76%			
	12	20	32			38%	95%	50%

Further GMP RT-PCR Format Testing

15

Following further improvements the single tube multiplexed RT-PCR assay in the GMP format was tested in 37 patients by adding 4 evaluable whole blood samples to the

- existing set of 33 bone marrow samples. Because bone marrow and whole blood samples generated equivalent raw Ct values for the three markers, they were merged in a single data set, which is summarized in Table 18. Receiver-operator characteristic (ROC) analysis indicated a discriminative value of the 2-gene ratio as 80% (AUC= 0.80) for
- 5 predicting overall response in a complete remission (CR) patient group used as response criteria corresponding to an overall response ORR (24%) computed as CR(9)/total patient n (37). This is illustrated in Figures 9 and 14. At the 2-gene ratio cutoff of 5.2 the assay sensitivity was 67% and specificity was 93%.

10

Table 18 merged data with results from whole blood and bone marrow samples		
Best Response	Patient Classification (J07901, baseline)	
NR	19	NR
SD	3	NR
CR	9	R
PR	4	NR
HI	2	NR
Total evaluable patients	37	28 NR vs. 9 R

With the definition of responders in Table 18, for the expanded patient set used in Table 18 the overall performance of the assay is described by Table 19.

EXAMPLE 4

This example shows, consistent with prior examples that the two-gene assay is specific for treatments that comprise an FTI. The synergistic presence of another agent
 5 does not appreciably reduce the requirement for an FTI for the two-gene assay to be effective.

While it is plain that in an identifiable subset of patients suffering from AML, which is identified by the 2-gene assay, it is possible to effectively treat such patients with combination therapies comprising an FTI, like Zarnestra, it has been expected that in
 10 the absence of an FTI in the combination therapy, the 2-gene assay will not be helpful.

To empirically assess the specificity of the 2-gene assay, it was tested on 41 samples from AML patients not treated with the FTI, Zarnestra to see if the response correlated with the 2-gene assay results. These AML patients were treated with

Table 19 GMP format performance with CR the only response criterion								
2-Gene Ratio Cutoff	Responder R	Non-Responder NR	Total	PPV	NPV	ORR	Spec	Sens
>5.2	6	2	8	75%				
≤5.2	3	26	29		90%			
	9	28	37			24%	93%	67%

15 traditional chemotherapeutic regimens consisting of ara-C, anthracyclines and VP16 (AcDVP16, n=23) and FLAM (n=18). Figure 10 shows that there was no significant association between the 2-gene ratio and clinical response or overall survival. Thus, these results further confirmed that the 2-gene ratio assay does not predict response to therapy in non-FTI-treated AML patients. The ROC AUC was determined to be 0.5,
 20 which demonstrates no significant value in predicting clinical response to chemotherapeutic regimens that do not include an FTI.

Furthermore, when subjects were classified as either high or low ratios based on the median of 2-gene ratio (0.959), 25th quantile (0.561), 75th quantile (1.248), there was

no demonstrated benefit in overall survival. Following survival analyses were performed:
1) all patients, 2) VP16 only and 3) FLAM only. The results (Figures 10 and 15, all
patients) showed there were no significant differences in overall survival (Days) between
the two groups stratified by median ratio as well as in 2 sub-groups stratified by treatment
5 regimen. This was also found to be the case when using cutpoints at the 25th and 75th
quantile (data not shown).

EXAMPLE 5

This example illustrates that not all sample collection techniques are equivalent.
10 Excessive RNA degradation and other sources of variability dependent on the sample
collection protocol can influence the two-gene assay.

The sample collection protocol typically requires the use of bone marrow samples
in prior implementations of the two-gene assay. This is not only quite intrusive, but also
painful for patients suffering from AML. The new protocol allows use of whole blood as
15 is described in this example.

To identify a preferred sample collection protocol (sample type) for the assay
equivalency testing study was performed between the two sample types (Bone Marrow
vs. Whole Blood) using three (3) collection protocols (Paxgene system vs. a standard
collection process in Heparin and EDTA tubes followed by a Ficoll-Paque centrifugation
20 method), respectively. 11 AML patients provided by the Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins University were tested.

Approximately 11 mL blood was drawn and 8-10 mL bone marrow was aspirated
from each patient using 3 collection methods for each of 2 sample types according to the
work flow depicted in Figure 11. The following six protocols were tested according to
25 this study design as depicted in Figure 11:

Protocol 1: PAXgene™ Bone Marrow System Catalog No. 764114 (PreAnalytix,
A QIAGEN / BD COMPANY). 2 mL volume of BMA was collected in PAXgene™
Bone Marrow tubes and shipped to VRX within 24 hrs at ambient temperature on
refrigerated cold packs. RNA was isolated upon receipt of the samples using PAXgene
30 Bone Marow RNA kit (Cat. No.764133).

Protocol 2: BMA collection was done in Sodium Heparin tubes (2 mL sample volume) and shipped to VRX within 24 hrs at ambient temp on refrigerated cold packs. Ficoll-Hypaque density gradient centrifugation step with direct freezing of cell pellets at -80C and RNA extraction using Qiagen Blood Midi kit was performed at Veridex.

5 **Protocol 3:** BMA collection was done in EDTA tubes (2 mL sample volume) and shipped to VRX within 24 hrs at ambient temp on refrigerated cold packs. Ficoll-Hypaque density gradient centrifugation step with direct freezing of cell pellets at -80C and RNA extraction using Qiagen[®] Blood Midi kit was performed at VERIDEX[®].

10 **Protocol 4:** PAXgene[™] Blood System. 2.5 mL blood was collected in PAXgene[™] Blood tubes (Cat. no. 762165, PreAnalytix, A QIAGEN / BD COMPANY) and shipped to VRX within 24 hrs at ambient temp on refrigerated cold packs. RNA was isolated at Veridex upon receipt of the samples using PAXgene Blood RNA kit (Cat. no. 762164)

15 **Protocol 5:** Whole blood collected in Sodium Heparin tubes (4mL Blood) was shipped to VRX within 24 hrs at ambient temp on refrigerated cold packs. Transfer of 3 mL blood to 4 mL CPT tube with subsequent Ficoll separation of mononuclear cells and direct freezing of cell pellets at -80C was performed at Veridex. RNA extraction was performed using Qiagen Blood Midi kit.

20 **Protocol 6:** Whole blood collected in EDTA tubes (4mL Blood) was shipped to VRX within 24 hrs at ambient temp on refrigerated cold packs. Transfer of 3 mL blood to 4 mL CPT tube with subsequent Ficoll separation of mononuclear cells and direct freezing of cell pellets at -80C was performed at Veridex. RNA extraction was performed using Qiagen Blood Midi kit.

25 Based on the results from Agilent BioAnalyzer QC, PAXGene system use resulted in good quality RNA targets for both bone marrow and blood samples for all eleven patients compared to Heparin and EDTA protocols, most commonly used in clinical laboratory settings.

30 A direct method of RNA integrity assessment (RNA QC) is to run RNA on Agilent BioAnalyzer and calculate RIN values (RNA Integrity Number). As recommended by Qiagen using PAXgene system, RNA with RIN 7 and above (to 10) is considered a good-quality target. Please see an additional data in Table 17 with RIN

values for the sample stability study with 11 patient samples. RIN values highlighted in yellow correspond to poor quality RNA samples (from Heparin and EDTA tubes).

PAXgene system in comparison with the other 2 types of collection tubes generated only good quality RNA based on the evaluable by yield samples. In Table 20, NE stands for not evaluated; NA stands for not available; a RIN value of about 2 to 5 indicates degraded RNA; and a RIN value of about 5 to 7 indicates marginal RNA.

Table 20 Correlation by RIN values between sample collection/processing protocols						
	Agilent Profile (RIN)					
	Blood			Marrow		
Sample ID	Heparin	EDTA	Paxgene	Heparin	EDTA	Paxgene
1	10.0	10.0	8.7	9.7	9.6	9.0
2	9.0	9.2	8.9	6.6	7.2	8.9
3	NE	NE	9.4	NE	2.1	8.9
4	9.6	9.6	NE	7.9	9.3	NE
5	9.3	8.3	8.0	7.3	7.3	8.4
6	5.7	6.7	9.1	3.2	3.6	9.1
7	NE	NE	9.8	NE	NE	NE
8	3.4	2.9	9.1	2.6	2.4	9.6
9	4.9	3.9	9.4	8.6	8.4	8.1
10	9.3	9.2	9.9	9.6	8.9	9.8
11	7.7	NA	9.2	6.6	5.8	9.5

Samples marked NE were not analyzed for the insufficient sample yields after the sample prep step.

Figure 12 (panels A and B) shows that bone marrow samples number 3 and 6 demonstrated substantial RNA degradation in Heparin tubes, which degradation elevated the values of 2-gene ratios. Raw Cts are inversely correlated with RIN values: for the lower RIN values the higher Cts are generated in all 3 channels in case of Heparin and EDTA protocols.

As is seen in Figures 12A and 12B, none of the samples exceed the threshold of 5 for the two-gene assay. The scatter in the measured two-gene ratio due to the collection protocol varies significantly as is Figure 12B. Patients 3 and 6 appear to have the most scatter with the Heparin and Paxgene bone marrow collection protocols defining the two extreme boundaries for these patients. An examination of the data in TABLE 20 shows that the whole blood collection protocols correlate well with each other while the same cannot be said for the bone marrow collection protocols. Indeed, based on Table 20 and Figure 12A and 12B, it can be argued that the two-gene assay should preferably be performed using whole blood. To ensure consistency, the PAXgene PB protocol is preferred. Without being bound by theory, it is believed that RNA degradation might be more rapidly occurring in bone marrow samples than in whole blood, thus lower level of correlation is demonstrated between EDTA (Heparin) tubes and PAXgene system.

Further, collection of bone marrow samples in heparin tubes appears to less reliable than other methods, a detail that should improve sample collection procedures in general for assays other than for just the two-gene assay disclosed here.

Pearson correlation coefficients (R2) and p-values for bone marrow (BM) and blood samples (PB) with the six (6) collection/processing protocols of Figure 11 are presented in Table 21. There is a good correlation observed between two-gene ratios for RNA samples obtained from Heparin, EDTA and PAXGene tubes in case of blood samples (values highlighted in red). However, there is a poor correlation observed between PAXGene bone marrow samples and other collection procedures. This observation is consistent with the lack of stabilization in Heparin tubes resulting in instability of RNA templates when bone marrow specimens are stored (shipped) under ambient conditions within 24 hrs before processing. These observations also support that PAXGene Whole Blood system as one of the preferred collection/processing protocols of this disclosure in view of the observed RNA integrity and reliability of 2-gene ratio values in such samples.

Table 21 Pearson correlation between sample collection/processing protocols					
	Heparin PB	Heparin BM	EDTA PB	EDTA BM	Paxgene PB
Heparin BM	0.936				
<u>p-value</u>	0				
EDTA BM	0.933	0.913			
<u>p-value</u>	0	0			
EDTA PB	0.714	0.683	0.784		
<u>p-value</u>	0.014	0.02	0.004		
Paxgene PB	0.816	0.839	0.917	0.717	
<u>p-value</u>	0.002	0.001	0	0.013	
Paxgene BM	0.323	0.329	0.383	0.635	0.453
<u>p-value</u>	0.333	0.323	0.246	0.036	0.162

EXAMPLE 6

This example, based in part on the patients described previously as part of Example 3, illustrates the adjustment of the tipifarnib dose to balance the toxicity with effective treatment of the patients with the aid of the two-gene assay to direct FTI combination therapy. This later analysis, performed in the context of determining better dosing strategies for tipifarnib and etoposide, also modified the analysis relating to RUO and GMP RT-PCR formats by treating CR as Responders, the rest being non-responders. The results of this later analysis have been presented in earlier described Examples.

DISCUSSION

Stratification of patient populations to predict therapeutic response is becoming increasingly valuable in the clinical management of cancer patients. For example, companion diagnostics are required for the stratification of patients who are candidates for targeted therapies such as trastuzumab (Herceptin, Genentech) in metastatic breast cancer, and cetuximab (Erbix, Merck) in colorectal cancer to provide quality care. Predictive biomarkers are also being utilized for imatinib (Gleevec, Novartis) in gastrointestinal stromal tumors, and for erlotinib (Tarceva, OSI Pharmaceuticals) and gefitinib (Iressa, Astra-Zeneca) in lung cancer. Currently there is no method available to predict response to a combination therapy that includes an FTI.

RASGRP1 was identified as the most robust single predictive gene expression marker with an overall predictive accuracy of 77% in the cross-validated training set for treatment with just an FTI. *RASGRP1* is a guanine nucleotide exchange factor (GEF) that specifically activates RAS. Expression of *RASGRP1* has been found in brain, T-cells, cells of monocytic lineage, and primitive hematopoietic precursors.

This disclosure provides the ratio of expression of *RASGRP1* and *APTX* as a robust predictor of response to FTI combination therapy. This two-gene classifier showed predictive utility in the discovery set of newly diagnosed AML.

The disclosed simple qPCR-based diagnostic assay has wider utility in the clinic than gene expression microarrays due to its ability to assay poor quality clinical samples that may not be profiled by current microarray technologies. Further, the assay can detect a signal in whole blood samples instead of requiring bone marrow cells. The methodology for selecting an external control for the assay, a simpler calculation of the ratio based on the sample, the external control and just *RASGRP1* and *APTX* makes it possible to offer patients, particularly elderly patients, the two-gene assay to determine whether a FTI combination therapy will assist them in fighting off AML.

The disclosed retrospective analysis of bone marrow aspirates collected in the context of the current tipifarnib + etoposide trial validate the 2-gene signature as a reproducible predictor of response to tipifarnib. The analysis also suggest that it is possible to prospectively discriminate those patients with AML who are likely to respond to tipifarnib vs. those who are not. The data substantiate the notion that the 2-gene

signature signature is relatively specific for tipifarnib (or a farnesyl transferase inhibitor), since there appeared to be no predictive relationship between the RASGRP1:APTX mRNA ratio and two intensive investigational chemotherapy regimens, each of which included ara-C and an anthracycline with a third agent (flavopiridol or etoposide).

5 Although the positive predictive value of the test in the context of the tipifarnib + etoposide Phase II trial was 78%, the negative predictive value (NPV) of the test was slightly lower (87%) than the NPV reported for tipifarnib monotherapy studies, which have been in the range of ~95%. This apparent discrepancy in NPV between single and combination therapies might relate, in part, to response to etoposide.

10 In summary, one skilled in the art will appreciate this disclosure is susceptible to many variations and alternative implementations without departing from its teachings or spirit. For instance, using an algebraic or mathematical variant of the two-gene ratio may be used to implement the method. The scope of the claims appended below includes many such modifications. Further, each reference discussed and cited herein is hereby
15 incorporated herein by reference in its entirety..

SEQUENCES

- RASGRP1* Amplicon SEQ No. 1
 5 ctggacgatctcattgacagctgcattcaatctttgatgcagatggaaacctgtgtcgaagtaaccaactgttgcaag
- APTX* Amplicon SEQ No. 2
 cgcttccgattgggctaccacgccattccgagtatgagccatgtacatcttcattgtgatcagccaggatttgattct
APTX UPPER PRIMER SEQ No. 3
 10 cgcttccgattgggctac
- APTX* LOWER PRIMER SEQ No.4
 agaatcaaaatcctggctgac
- 15 *RASGRP1* UPPER PRIMER SEQ No. 5
 ctggacgatctcattgacagctgcattcaatctttgatgcagatggaaacctgtgtcgaagtaaccaactgttgcaag
- RASGRP1* LOWER PRIMER SEQ No.6
 20 cttgcaacagttggttacttcg,
- HMBS* Amplicon SEQ No. 7
 ccttgcccactgtgcttctccctggcttcaccatcggagccatctgcaagcgggaaaaccctcatgat
- HMBS* UPPER PRIMER SEQ No. 8
 25 cctgcccactgtgcttct
- HMBS* LOWER PRIMER SEQ No.9
 atcatgagggttttcccgt
- 30 *RASGRP1* TAQMAN PROBE SEQ No. 10
 FAM-cattcaatctttgatgcagatggaaacctg-BHQ1
- APTX* TAQMAN PROBE SEQ No. 11
 Gold 540-cacgccattccgagtatgagccatgtac-BHQ2
 35
- HMBS* TaqMan probe, SEQ No. 12
 Cy5-gcttcaccatcggagccatctgca-BHQ1,
 40

REFERENCES

- Ahel et al. (2006) The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates *Nature* 443:713-716
- Baylin et al. in *Nature Clinical Practice* (2005) 2:S1-S3
- 5 Bivona et al. (2003) Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1 *Nature* 424:694-698
- Bos (1989) ras oncogenes in human cancer: a review *Cancer Res* 49:4682-4689
- Bullinger et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia *N Engl J Med* 350:1605-1616
- 10 Burger et al. (2005) Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes *Cancer Biol Ther* 4:1270-1274
- Chang et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer *Lancet* 362:362-369
- 15 Chen et al. (2005) FLT3/ITD mutation signaling includes suppression of SHP-1 *J Biol Chem* 280:5361-5369
- Cox et al (2002) Farnesyltransferase inhibitors: promises and realities *Curr Opin Pharmacol* 2:388-393
- Ebinu et al. (1998) RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs *Science* 280:1082-1086
- 20 Ehmann et al. (2006) Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations *Leuk Lymphoma* 47:1387-1391
- End et al. (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro *Cancer Res* 61:131-137
- 25 Feldkamp et al. (2001) Isotype-specific RasGTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status *Cancer Res* 61:4425-4431
- Geman et al. (2004) Classifying gene expression profiles from pairwise mRNA comparisons *Stat Appl Genet Mol Biol* 3:30
- 30

Holleman et al. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment *N Engl J Med* 351:533-542

Illmer et al. (2005) Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts *Clin Cancer Res* 11:3217-322

Jansen et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling *J Clin Oncol* 23:732-740

Karp et al. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial *Blood* 97:3361-3369

Karp, Karen Flatten, Eric J. Feldman, Jacqueline M. Greer et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. *Blood* 2009, 113:4841-4852.

Kawasaki et al. (1998) A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia *Proc Natl Acad Sci* 95:13278-13283

Lancet et al. (2006) A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia *Blood* 2:2

Leith et al. Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study. *Blood*, Vol. 89, 1997: pp. 3323-3329.

Lossos et al. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes *N Engl J Med* 350:1828-1837

Lubet et al. (2006) Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations *Mol Cancer Ther* 5:1073-1078

Lynch et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib *N Engl J Med* 350:2129-2139

Ma et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen *Cancer Cell* 5:607-616

Mesa et al (2006) Tipifarnib: farnesyl transferase inhibition at a crossroads *Expert Rev Anticancer Ther* 6:313-319

5 Moroni et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study *Lancet Oncol* 6:279-286

Perez de Castro et al. (2004) A Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus *Mol Cell Biol* 24:3485-3496

10 Potti et al. (2006) Genomic signatures to guide the use of chemotherapeutics *Nat Med* 12:1294-1300

Raponi M, Wang Y, and Hongtao F. WO2008112749 A1. Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase.

15 Raponi M, Harousseau JL, Lancet JE, et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. *Clin Cancer Res.* 2007;13: 2254-2260.

Raponi, Jeffrey E. Lancet, Hongtao Fan, Lesley Dossey, Grace Lee, Ivana Gojo, Eric J. Feldman, Jason Gotlib, Lawrence E. Morris, Peter L. Greenberg, John J. Wright, Jean-Luc Harousseau, Bob Lowenberg, Richard M. Stone, Peter De Porre, Yixin Wang, and Judith E. Karp. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. *Blood* 2008, 111: 2589-2596.

20 Rao et al. (2004) Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer *J Clin Oncol* 22:3950-3957

Reuter et al. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? *Blood* 96:1655-1669

Reuther et al. (2001) Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA *J Biol Chem* 276:27145-27151

- Reuther et al. (2002) RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia J Biol Chem 277:30508-30514
- Rosenwald et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346:1937-1947
- 5 Rowinsky et al (1999) Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development J Clin Oncol 17:3631-3652
- Sahai et al. (2002) RHO-GTPases and cancer Nat Rev Cancer 2:133-142
- Seidman et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene
- 10 amplification J Clin Oncol 19:2587-2595
- Ship et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8:68-74
- Solit et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition Nature 439:358-362
- 15 Sterpetti et al. (1999) Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting Mol Cell Biol 19:1334-1345
- Stone (2006) Regulation of Ras in lymphocytes: get a GRP Biochem Soc Trans 34:858-861
- 20 Tognon et al. (1998) Regulation of RasGRP via a phorbol ester-responsive C1 domain Mol Cell Biol 18:6995-7008
- Tsao et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353:133-144
- Van Cutsem et al. (2004) Phase III trial of gemcitabine plus tipifarnib compared
- 25 with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22:1430-1438
- Waters et al. (2006) Developing gene expression signatures of pathway deregulation in tumors Mol Cancer Ther 5:2444-2449
- Weinstein et al. (2006) Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy Nat Clin Pract Oncol 3:448-457
- 30 White et al. (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272:14459-14464

Yeoh et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Cancer Cell 1:133-143

CLAIMS

1. A method for administering tipinifarb and etoposide to a patient diagnosed with a disorder, the method comprising:
determining if a ratio of RASGRP1 and APTX expression, each level computed
5 using the $\Delta\Delta\text{Ct}$ method, exceeds a $\Delta\Delta\text{Ct}$ threshold corresponding to a specified sensitivity or specificity or a maximized sum of sensitivity and specificity in a ROC analysis in a test population; and
administering a therapeutically effective amount of tipifarnib if the ratio exceeds the $\Delta\Delta\text{Ct}$ threshold.
- 10 2. The method of claim 1 wherein the ratio of RASGRP1 and APTX expression is determined using at least one primer from the group consisting of
(i) 5'-CGCTTCCGATTGGGCTAC-3'
(ii) 5'- AGAATCAAAATCCTGGCTGATC-3'
(iii) 5'- CTGGACGATCTCATTGACAGC-3' and
15 (iv) 5'- CTTGCAACAGTTGGTTACTTCG -3'.
3. The method of claim 1 wherein a level of expression of RASGPR1 is estimated relative to one or more of the group consisting of APTX, beta-actin and HMBS.
4. The method of claim 1 wherein the $\Delta\Delta\text{Ct}$ threshold is about 5.2.
5. The method of claim 1 wherein the $\Delta\Delta\text{Ct}$ threshold corresponds to an area under
20 the curve of about 70% or more.
6. The method of claim 1, wherein the assay is performed in a single tube in a multiplex format.
7. The method of claim 2 further comprising determining a ratio of expression levels of RASGRP1 relative to APTX using an external control.
- 25 8. The method of claim 7, wherein the external control is selected from the group consisting of one or more reference cell lines, JY RNA, Universal RNA, a standardized RNA reference and a reference patient sample.
9. The method of claim 1, wherein a sample comprises at least one of
(i) a bone marrow sample; and
30 (ii) a blood sample.

10. The method of claim 1 wherein the patient is treated with tipifarnib and another agent synergistic with tipifarnib, wherein the another agent synergistic with tipifarnib is one of or a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatinum.
11. The method of claim 1, wherein the disorder is AML.
12. A method for prescribing tipinifarb to a subject diagnosed with a disorder, the method comprising:
evaluating expression of RASGRP1 and APTX in an amplification of signals from ribonucleic acid targets using at least one primer from the group consisting of
(i) 5'-CGCTTCCGATTGGGCTAC-3'
(ii) 5'- AGAATCAAAATCCTGGCTGATC-3'
(iii) 5'- CTGGACGATCTCATTGACAGC-3' and
(iv) 5'- CTTGCAACAGTTGGTTACTTCG -3'.
13. The method of claim 12 wherein a ratio of expression of genes RASGPR1 is estimated relative to the expression levels of APTX.
14. The method of claim 12, wherein the assay is performed in a single tube in a multiplex format.
15. The method of claim 13 further comprising determining a ratio of expression levels of RASGRP1 relative to APTX using an external control.
16. The method of claim 15 wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a $\Delta\Delta C_t$ threshold value of about 5.2.
17. The method of claim 15 wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a $\Delta\Delta C_t$ threshold value of about 4.7.
18. The method of claim 15 wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a threshold value corresponding to a specified sensitivity or specificity or a maximized sum of sensitivity and specificity in a ROC analysis.
19. The method of claim 18 wherein an area under the curve is about 70% or more.

20. The method of claim 15, wherein the external control is selected from the group consisting of one or more reference cell lines, JY RNA, Universal RNA, a standardized RNA reference and a reference patient sample.
21. The method of claim 12, wherein a sample comprises at least one of
- 5 (i) a bone marrow sample; and
- (ii) a blood sample.
22. The method of claim 15 wherein if the ratio of expression levels of RASGRP1 relative to APTX in a subject is greater than a threshold the subject is prescribed tipifarnib.
- 10 23. The method of claim 17 wherein tipifarnib is prescribed with another agent synergistic with tipifarnib, wherein the another agent synergistic with tipifarnib is one of or a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatinum.
- 15 24. The assay of claim 19, wherein the another agent synergistic with the farnesyl transferase inhibitor is etoposide.
25. A method of identifying a treatment for a subject diagnosed with a myeloid disorder, the method comprising:
- administering a first assay having a first outcome based on at least an
- 20 amplification of a target ribonucleic acid;
- flagging the subject based on the first outcome and a predetermined threshold as unlikely to be aided by a one or more of a group of treatments, each of which treatments requires administration of a farnesyl transferase inhibitor and a synergistic agent selected from the group consisting of etoposide, teniposide,
- 25 tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum; and
- selecting, in response to the subject not being flagged, a treatment from the group of treatments.
26. The method of claim 25, wherein the predetermined threshold is selected to have
- 30 a high negative predictive value for a response to one or more of the group of treatments.

27. The method of claim 25, wherein the predetermined threshold is selected to have a high positive predictive value to one or more of the group of treatments.
28. The method of claim 25 further comprising selecting the treatment based on a relative positive predictive value of the treatment.
- 5 29. The method of claim 25, wherein the myeloid disorder is acute myeloid leukemia.
30. The method of claim 25 further comprising the step of changing from a past treatment to the future treatment in response to detecting a reduction in response to the past treatment.
- 10 31. The method of claim 25 wherein a positive predictive value of the first assay is determined based on a fraction of subjects expected to exhibit a positive response to a treatment with a farnesyl transferase inhibitor, wherein the positive response comprises complete remission.
- 15 32. The method of claim 31, wherein complete remission is defined by a presence of less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/ μ L and a platelet count of at least 100,000/ μ L, absence of blasts in peripheral blood, absence of identifiable leukemic cells in bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease.
- 20 33. The method of claim 32, wherein the positive response further includes one or more of partial remission and hematologic improvement.
- 25 34. The method of claim 33, wherein partial remission is defined by presence of trilineage hematopoiesis in the bone marrow with recovery of ANC and platelets to the above stated levels, but with 5 to 25% bone marrow blasts, and at least 50% decrease in bone marrow blast percentage from baseline; and hematologic improvement is defined by at least a 50% decrease in marrow blasts or decrease in any measurable extramedullary disease, recovery of ANC to 500 to 1000/ μ L, platelet count to 20,000 to 100,000/ μ L, or improvement in transfusion requirements.
- 30 35. An assay for identifying subjects likely to respond to a treatment comprising administration of farnesyl transferase inhibitors by evaluating the expression of RASGRP1 and APTX in an amplification of signals from ribonucleic acid targets

using at least one primer from the group consisting of

(i) 5'-CGCTTCCGATTGGGCTAC-3'

(ii) 5'-AGAATCAAAATCCTGGCTGATC-3'

(iii) 5'-CTGGACGATCTCATTGACAGC-3' and

5 (iv) 5'-CTTGCAACAGTTGGTTACTTCG-3'.

36. The assay of claim 35 wherein a level of expression of genes RASGPR1 is estimated relative to one or more of the group consisting of APTX, beta-actin and HMBS.

10 37. The assay of claim 35, wherein the assay is performed in a single tube in a multiplex format.

38. The assay of claim 35 further comprising determining a ratio of expression levels of RASGRP1 relative to APTX using an external control.

15 39. The assay of claim 37, wherein the external control is selected from the group consisting of one or more reference cell lines, JY RNA, Universal RNA, a standardized RNA reference and a reference patient sample.

40. The assay of claim 35, wherein a sample comprises at least one of
(i) a bone marrow sample; and
(ii) a blood sample.

20 41. The assay of claim 38 wherein if the ratio in a subject is greater than a predetermined threshold the subject is classified as a likely responder to administration of a farnesyl transferase inhibitor with another agent synergistic with the farnesyl transferase inhibitor, wherein the another agent synergistic with the farnesyl transferase inhibitor is one of or a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib,
25 paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatinum.

42. The assay of claim 41, wherein the farnesyl transferase inhibitor is tipifarnib and the another agent synergistic with the farnesyl transferase inhibitor is etoposide.

30 43. A method of selecting a threshold in an assay for identifying a responder to a treatment with a combination of a farnesyl inhibitor and another agent, which is selected from or is a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide,

- Topotecan, Trastuzumab and cisplatinum, the method comprising:
 processing a blood sample to prepare a ribonucleic acid enriched preparation;
 generating a ratio of expression levels RASGRP1 and APTX; and
 maximizing in a data set one or more of a measure from the set consisting of a
 positive predictive value of the treatment, a negative predictive value of
 identifying a responder, an AUC in a ROC analysis, a sensitivity and a specificity,
 wherein the ratio of expression levels RASGRP1 and APTX is compared to the
 threshold.
44. The method of claim 43, wherein the expression level of RASGRP1 is measured
 using RT-PCR.
45. The method of claim 44, wherein the expression level of RASGRP1 is evaluated
 relative to the threshold determined to correspond to a particular reference RNA
 standard.
46. A method for administering tipinifarb and etoposide to a patient diagnosed with a
 Acute Mylogenous Leukemia, the method comprising:
 determining if a ratio of RASGRP1 and APTX expression, each level computed
 using the delta-delta-Ct method, exceeds a $\Delta\Delta\text{Ct}$ threshold corresponding to a
 sensitivity or specificity or a maximized sum of sensitivity and specificity in a
 ROC analysis in a test population; and
 administering a therapeutically effective amount of tipifarnib if the ratio exceeds
 the $\Delta\Delta\text{Ct}$ threshold.
47. The method of claim 46 wherein the ratio of RASGRP1 and APTX expression is
 determined using at least one primer from the group consisting of
 (i) 5'-CGCTTCCGATTGGGCTAC-3'
 (ii) 5'- AGAATCAAAATCCTGGCTGATC-3'
 (iii) 5'- CTGGACGATCTCATTGACAGC-3' and
 (iv) 5'- CTTGCAACAGTTGGTTACTTCG -3'.
48. The method of claim 46 wherein a level of expression of RASGPR1 is estimated
 relative to one or more of the group consisting of APTX, beta-actin and HMBS.
49. The method of claim 46 wherein the $\Delta\Delta\text{Ct}$ threshold is about 5.2.

50. The method of claim 46 wherein the $\Delta\Delta C_t$ threshold corresponds to an area under the curve of about 70% or more.
51. The method of claim 46, wherein the assay is performed in a single tube in a multiplex format.
- 5 52. The method of claim 47 further comprising determining a ratio of expression levels of RASGRP1 relative to APTX using an external control.
53. The method of claim 42, wherein the external control is selected from the group consisting of one or more reference cell lines, JY RNA, Universal RNA, a standardized RNA reference and a reference patient sample.
- 10 54. The method of claim 46, wherein a sample comprises at least one of
(i) a bone marrow sample; and
(ii) a blood sample.
55. The method of claim 46 wherein the patient is treated with tipifarnib and another agent synergistic with tipifarnib, wherein the another agent synergistic with
15 tipifarnib is one of or a derivative of a member selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, Temozolomide, Topotecan, Trastuzumab and cisplatin.
56. The method of claim 46, wherein said patient diagnosed with Acute Mylogenous Leukemia is 55 years of age or older, preferably 60 years of age or older, and
20 even more preferably, 65 years of age or older.

A

	PD	R	
False	8	1	9
True	5	12	17
	13	13	26

Sensitivity=92.3%
Specificity=61.5%
NPV=88.9%
PPV=70.6%
Prevalence=50%

B





FIG. 1

B



D




FIG. 2

A

	PD	R	
False	12	2	14
True	1	11	12
	13	13	26

Sensitivity=84.6%
Specificity=92.3%
NPV=85.7%
PPV=91.7%
Prevalence=50%

C

	PD	R	
False	23	2	25
True	21	8	29
	44	10	54

Sensitivity=80%
Specificity=52.3%
NPV=92%
PPV=27.6%
Prevalence=18.5%
Odds ratio =4.38%





FIG. 3



A

	PD	R	
False	24	3	27
True	20	7	27
	44	10	54

Sensitivity=70%

Specificity=54.5%

NPV=88.9%

PPV=25.9%

Prevalence=18.5%

FIG. 4

5/16






FIG. 5

6/16

**FIG. 6**

7/16

Titration Curves in Triplex RT-PCR format:
Ct values Over Log RNA input in ng

**FIG. 7**

8/16

Overall survival




FIG. 8

9/16



**FIG. 9**

FIG. 10


2-Gene qPCR Assay Does Not Predict Response in Non-FTI-Treated AML

23 AcDVP16 (median age= 39, 23-66), 61% CR
18 FLAM (median age= 64, 42-71), 61% CR
Bone marrow samples only, Judy Karp
qPCR Assay
ROC AUC= 0.54, No predictive value
for enriching responders


OS of AML patients treated with FLAM stratified by high vs. low 2-gene ratio



OS of AML patients treated with FLAM or VP16 stratified by high vs. low 2-gene ratio



OS of AML patients treated with VP16 stratified by high vs. low 2-gene ratio



Stability study protocol comparing BMA vs. Blood PBMC samples




FIG. 11




FIG. 12A

13/16




FIG. 12B

Sheet 14/16

2-Gene Ratio Cutoff	Responder CR	Non- Responder NR	Total	PPV	NPV	ORR	Spec	Sens
>5.2	7	2	9	78%				
≤5.2	4	27	31		87%			
	11	29	40			28%	93%	64%





FIG. 13

15/16

A**FIG. 14**

16/16




FIG. 15

Overall survival




FIG. 8